366 results on '"Zarko Alfirevic"'
Search Results
2. Assessing the usefulness of randomised trials in obstetrics and gynaecology
- Author
-
Janneke van ’t Hooft, Charlotte E. van Dijk, Cathrine Axfors, Zarko Alfirevic, Martijn A. Oudijk, Khalid S. Khan, Ben W. J. Mol, Patrick M. Bossuyt, John P. A. Ioannidis, Graduate School, APH - Personalized Medicine, APH - Quality of Care, ARD - Amsterdam Reproduction and Development, Obstetrics and Gynaecology, Epidemiology and Data Science, and APH - Methodology
- Subjects
Obstetrics and Gynecology - Published
- 2023
3. Methods of induction of labour: a network meta-analysis
- Author
-
Siwanon Rattanakanokchai, Ioannis D Gallos, Chumnan Kietpeerakool, Nuntasiri Eamudomkarn, Zarko Alfirevic, Olufemi T Oladapo, Doris Chou, Ben Willem J Mol, Wentao Li, Pisake Lumbiganon, Arri Coomarasamy, and Malcolm J Price
- Subjects
Pharmacology (medical) - Published
- 2023
4. Induction of labour: first, do no harm
- Author
-
Andrew D Weeks and Zarko Alfirevic
- Subjects
Labor, Obstetric ,Pregnancy ,Humans ,Female ,General Medicine ,Labor, Induced - Published
- 2022
5. Foetal loss after chorionic villus sampling and amniocentesis in twin pregnancies: A multicentre retrospective cohort study
- Author
-
Kate Navaratnam, Delima Khairudin, Robyn Chilton, Andrew Sharp, George Attilakos, Daniel Stott, Sophie Relph, Rebecca Spencer, Dominique A. Badr, Andrew Carlin, Jacques Jani, Mark D. Kilby, Mercede Sebghati, Asma Khalil, and Zarko Alfirevic
- Subjects
Fetus ,Chorionic Villi Sampling ,Pregnancy ,Amniocentesis ,Pregnancy, Twin ,Obstetrics and Gynecology ,Humans ,Female ,Genetics (clinical) ,Retrospective Studies - Abstract
OBJECTIVE: We aimed to determine foetal losses for DCDA and MCDA twins following transabdominal CVS or amniocentesis performed
- Published
- 2022
6. Developing a topic-based repository of clinical trial individual patient data: experiences and lessons learned from a pilot project
- Author
-
Lesley A. Stewart, Catrin Tudur Smith, Anna Cuthbert, Nancy Medley, Zarko Alfirevic, and Richard Crew
- Subjects
Knowledge management ,Medicine (miscellaneous) ,Pilot Projects ,Reuse ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Humans ,030212 general & internal medicine ,business.industry ,Information Dissemination ,030503 health policy & services ,Individual participant data ,Repository ,Patient data ,Investment (macroeconomics) ,Research Personnel ,Data sharing ,Clinical trial ,IPD ,Commentary ,Position (finance) ,Individual patient data ,0305 other medical science ,business ,Host (network) ,Barriers - Abstract
Background Building a dataset of individual participant data (IPD) for meta-analysis represents considerable research investment as well as collaboration across multiple institutions and researchers. Making arrangements to curate and share the dataset beyond the IPD meta-analysis project for which it was established, for reuse in future research projects, would maximise the value of this investment. Methods Our aim was to establish the Cochrane repository for individual patient data from clinical trials in pregnancy and childbirth (CRIB) as an example of how an IPD repository could become part of Cochrane infrastructure. We believed that establishing CRIB under Cochrane auspices would engender trust and encourage trial investigators to share data, and at the same time position Cochrane to take steps towards expanding the number of reviews with IPD synthesis. Results CRIB was designed as a web-based platform to receive, host and facilitate onward sharing of de-identified data. Development was not straightforward and we did not fully achieve our aim as intended. We describe the challenges encountered and suggest ways that future repositories might overcome these. In particular, securing the legal agreements required to facilitate data sharing proved to be the main barrier, being time-consuming and more complex than anticipated. Conclusions We would recommend that researchers conducting IPD meta-analysis should consider discussing the option to transfer the curated IPD datasets to a repository at the end of the initial meta-analysis and this should be recognised within the data sharing agreements made with the original data contributors.
- Published
- 2021
7. Interventions to Prevent Spontaneous Preterm Birth in Women With Singleton Pregnancy Who Are at High Risk: Systematic Review and Network Meta-Analysis
- Author
-
Angharad Care, Sarah J Nevitt, Nancy Medley, Sarah Donegan, Laura Good, Lynn Hampson, Catrin Tudur Smith, and Zarko Alfirevic
- Subjects
Administration, Intravaginal ,Treatment Outcome ,Pregnancy ,Management of Technology and Innovation ,Network Meta-Analysis ,Obstetrics and Gynecology ,Humans ,Premature Birth ,Bayes Theorem ,Female ,General Medicine ,Progesterone ,Randomized Controlled Trials as Topic - Abstract
ObjectivesTo compare the efficacy of bed rest, cervical cerclage (McDonald, Shirodkar, or unspecified type of cerclage), cervical pessary, fish oils or omega fatty acids, nutritional supplements (zinc), progesterone (intramuscular, oral, or vaginal), prophylactic antibiotics, prophylactic tocolytics, combinations of interventions, placebo or no treatment (control) to prevent spontaneous preterm birth in women with a singleton pregnancy and a history of spontaneous preterm birth or short cervical length.DesignSystematic review with bayesian network meta-analysis.Data sourcesThe Cochrane Pregnancy and Childbirth Group’s Database of Trials, the Cochrane Central Register of Controlled Trials, Medline, Embase, CINAHL, relevant journals, conference proceedings, and registries of ongoing trials.Eligibility criteria for selecting studiesRandomised controlled trials of pregnant women who are at high risk of spontaneous preterm birth because of a history of spontaneous preterm birth or short cervical length. No language or date restrictions were applied.OutcomesSeven maternal outcomes and 11 fetal outcomes were analysed in line with published core outcomes for preterm birth research. Relative treatment effects (odds ratios and 95% credible intervals) and certainty of evidence are presented for outcomes of preterm birth ResultsSixty one trials (17 273 pregnant women) contributed data for the analysis of at least one outcome. For preterm birth ConclusionVaginal progesterone should be considered the preventative treatment of choice for women with singleton pregnancy identified to be at risk of spontaneous preterm birth because of a history of spontaneous preterm birth or short cervical length. Future randomised controlled trials should use vaginal progesterone as a comparator to identify better treatments or combination treatments.Systematic review registrationPROSPERO CRD42020169006
- Published
- 2022
8. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials
- Author
-
Lesley A Stewart, Mark Simmonds, Lelia Duley, Alexis Llewellyn, Sahar Sharif, Ruth AE Walker, Lucy Beresford, Kath Wright, Mona M Aboulghar, Zarko Alfirevic, Azam Azargoon, Rashmi Bagga, Elham Bahrami, Sean C Blackwell, Steve N Caritis, C Andrew Combs, Jennifer M Croswell, Caroline A Crowther, Anita F Das, Kay Dickersin, Kristina C Dietz, Andrew Elimian, William A Grobman, Alexander Hodkinson, Kimberley A Maurel, David S McKenna, Ben W Mol, Kelle Moley, Jamie Mueller, Anwar Nassar, Jane E Norman, John Norrie, John M O'Brien, Raphael Porcher, Shalini Rajaram, Line Rode, Dwight J Rouse, Carol Sakala, Ewoud Schuit, Marie-Victoire Senat, Joe L Simpson, Katherine Smith, Anne Tabor, Elizabeth A Thom, Melanie A van Os, Evelyn P Whitlock, Stephen Wood, Tom Walley, and Obstetrics and Gynaecology
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Pregnancy, High-Risk ,030204 cardiovascular system & hematology ,progesterone ,Injections, Intramuscular ,Risk Assessment ,Miscarriage ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,medicine ,Humans ,030212 general & internal medicine ,Progesterone ,Randomized Controlled Trials as Topic ,Progestogen ,Obstetrics ,business.industry ,17-alpha-Hydroxyprogesterone ,Absolute risk reduction ,Infant, Newborn ,Pregnancy Outcome ,Obstetrics and Gynecology ,Preterm birth ,General Medicine ,medicine.disease ,17-alpha-hydroxyprogesterone ,Administration, Intravaginal ,Meta-analysis ,Relative risk ,Premature Birth ,Female ,pregnancy ,Outcomes research ,business ,Premature rupture of membranes ,Decision Making, Shared - Abstract
BACKGROUND: Preterm birth is a global health priority. Using a progestogen during high-risk pregnancy could reduce preterm birth and adverse neonatal outcomes.METHODS: We did a systematic review of randomised trials comparing vaginal progesterone, intramuscular 17-hydroxyprogesterone caproate (17-OHPC), or oral progesterone with control, or with each other, in asymptomatic women at risk of preterm birth. We identified published and unpublished trials that completed primary data collection before July 30, 2016, (12 months before data collection began), by searching MEDLINE, Embase, CINAHL, the Maternity and Infant Care Database, and relevant trial registers between inception and July 30, 2019. Trials of progestogen to prevent early miscarriage or immediately-threatened preterm birth were excluded. Individual participant data were requested from investigators of eligible trials. Outcomes included preterm birth, early preterm birth, and mid-trimester birth. Adverse neonatal sequelae associated with early births were assessed using a composite of serious neonatal complications, and individually. Adverse maternal outcomes were investigated as a composite and individually. Individual participant data were checked and risk of bias assessed independently by two researchers. Primary meta-analyses used one-stage generalised linear mixed models that incorporated random effects to allow for heterogeneity across trials. This meta-analysis is registered with PROSPERO, CRD42017068299.FINDINGS: Initial searches identified 47 eligible trials. Individual participant data were available for 30 of these trials. An additional trial was later included in a targeted update. Data were therefore available from a total of 31 trials (11 644 women and 16185 offspring). Trials in singleton pregnancies included mostly women with previous spontaneous preterm birth or short cervix. Preterm birth before 34 weeks was reduced in such women who received vaginal progesterone (nine trials, 3769 women; relative risk [RR] 0·78, 95% CI 0·68-0·90), 17-OHPC (five trials, 3053 women; 0·83, 0·68-1·01), and oral progesterone (two trials, 181 women; 0·60, 0·40-0·90). Results for other birth and neonatal outcomes were consistently favourable, but less certain. A possible increase in maternal complications was suggested, but this was uncertain. We identified no consistent evidence of treatment interaction with any participant characteristics examined, although analyses within subpopulations questioned efficacy in women who did not have a short cervix. Trials in multifetal pregnancies mostly included women without additional risk factors. For twins, vaginal progesterone did not reduce preterm birth before 34 weeks (eight trials, 2046 women: RR 1·01, 95% CI 0·84-1·20) nor did 17-OHPC for twins or triplets (eight trials, 2253 women: 1·04, 0·92-1·18). Preterm premature rupture of membranes was increased with 17-OHPC exposure in multifetal gestations (rupture INTERPRETATION: Vaginal progesterone and 17-OHPC both reduced birth before 34 weeks' gestation in high-risk singleton pregnancies. Given increased underlying risk, absolute risk reduction is greater for women with a short cervix, hence treatment might be most useful for these women. Evidence for oral progesterone is insufficient to support its use. Shared decision making with woman with high-risk singleton pregnancies should discuss an individual's risk, potential benefits, harms and practicalities of intervention. Treatment of unselected multifetal pregnancies with a progestogen is not supported by the evidence.FUNDING: Patient-Centered Outcomes Research Institute.
- Published
- 2021
9. Foley catheter vs oral misoprostol for induction of labor: individual participant data meta‐analysis
- Author
-
M. Goonewardene, Katrien Oude Rengerink, K.W. Bloemenkamp, Heidi Kruit, Zarko Alfirevic, M. Flanagan, Hillary Bracken, M L G Ten Eikelder, S. Goni, Andrew Weeks, Wentao Li, Ben W.J. Mol, Shuchita Mundle, J. I. Kemper, and Kirsten R Palmer
- Subjects
medicine.medical_specialty ,Catheters ,Neonatal intensive care unit ,Foley catheter ,Administration, Oral ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Pregnancy ,law ,Oxytocics ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Labor, Induced ,030212 general & internal medicine ,Misoprostol ,Randomized Controlled Trials as Topic ,030219 obstetrics & reproductive medicine ,Radiological and Ultrasound Technology ,Obstetrics ,business.industry ,Obstetrics and Gynecology ,Gestational age ,General Medicine ,16. Peace & justice ,medicine.disease ,Intensive care unit ,3. Good health ,Reproductive Medicine ,Relative risk ,Female ,Maternal death ,Urinary Catheterization ,business ,medicine.drug - Abstract
Objective To compare the effectiveness and safety of Foley catheter and oral misoprostol for induction of labor (IOL). Methods The Cochrane Review on Mechanical Methods for Induction of Labour and Ovid MEDLINE, EMBASE via Ovid, Ovid Emcare, CINAHL Plus, ClinicalTrials.gov and Scopus, from inception to April 2019, were searched for randomized controlled trials (RCTs) comparing Foley catheter to oral misoprostol for IOL in viable singleton gestations. Eligible trials for which raw data were obtained were included and individual participant data meta-analysis was performed. Primary outcomes were vaginal birth, a composite of adverse perinatal outcome (including stillbirth, neonatal death, neonatal seizures, admission to the neonatal intensive care unit, severe respiratory compromise or meconium aspiration syndrome) and a composite of adverse maternal outcome (including admission to the intensive care unit, maternal infection, severe postpartum hemorrhage, maternal death or uterine rupture). The quality of the included RCTs was assessed using the Cochrane Risk of Bias 2 tool and the certainty of evidence was evaluated using the GRADE approach. A two-stage random-effects model was used for meta-analysis according to the intention-to-treat principle and interactions between treatment and baseline characteristics were assessed. Results Of seven eligible trials, four provided individual participant data for a total of 2815 participants undergoing IOL, of whom 1399 were assigned to Foley catheter and 1416 to oral misoprostol. All four trials provided data for each of the primary outcomes in all 2815 women. Compared with those receiving oral misoprostol, Foley catheter recipients had a slightly decreased chance of vaginal birth (risk ratio (RR), 0.95 (95% CI, 0.91-0.99); I2 , 2.0%; moderate-certainty evidence). A trend towards a lower rate of composite adverse perinatal outcome was found in women undergoing IOL using a Foley catheter compared with oral misoprostol (RR, 0.71 (95% CI, 0.48-1.05); I2 , 14.9%; low-certainty evidence). Composite adverse maternal outcome did not differ between the groups (RR, 1.00 (95% CI, 0.97-1.03); I2 , 0%; moderate-certainty evidence). Meta-analyses of effect modifications did not show significant interactions between intervention and parity or gestational age for any of the primary outcomes. Conclusions For women undergoing IOL, Foley catheter is less effective than oral misoprostol, as it was associated with fewer vaginal births. However, while we found no significant difference in maternal safety, Foley catheter induction may reduce adverse perinatal outcomes. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.
- Published
- 2021
10. Controversies in the prevention of spontaneous preterm birth in asymptomatic women: an evidence summary and expert opinion
- Author
-
Angharad Care, Zarko Alfirevic, and Laura Goodfellow
- Subjects
Pessary ,medicine.medical_specialty ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,medicine.medical_treatment ,Obstetrics and Gynecology ,Vaginal pessary ,Cervical shortening ,Asymptomatic ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Risk Factors ,Expert opinion ,Genital tract ,medicine ,Humans ,Premature Birth ,Female ,Cervical cerclage ,medicine.symptom ,business ,Risk Reduction Behavior ,Cervical length - Abstract
Preterm birth prevention is multifaceted and produces many nuanced questions. This review addresses six important clinical questions about preterm birth prevention as voted for by members of the UK Preterm Clinical Network. The questions cover the following areas: preterm birth prevention in 'low-risk' populations; screening for asymptomatic genital tract infection in women at high risk of preterm birth; cervical length screening with cerclage or vaginal pessary in situ; cervical shortening whilst using progesterone; use of vaginal progesterone in combination with cervical cerclage; and optimal advice about intercourse for women at high risk of preterm birth.
- Published
- 2020
11. Amnioinfusion versus Usual Care in Women with Prelabor Rupture of Membranes in Midtrimester: A Systematic Review and Meta-Analysis of Short- and Long-Term Outcomes
- Author
-
Annemijn A. de Ruigh, Noor E. Simons, Larissa I. van der Windt, Sofie H. Breuking, Janneke van ‘t Hooft, Augustinus S. van Teeffelen, Zarko Alfirevic, Devender Roberts, Ben W. Mol, Eva Pajkrt, Obstetrics and gynaecology, and Amsterdam Reproduction & Development (AR&D)
- Subjects
Embryology ,Fetal Membranes, Premature Rupture ,Perinatal Death ,Infant, Newborn ,Obstetrics and Gynecology ,Infant ,Obstetric ,General Medicine ,Second ,Newborn ,Delivery, Obstetric ,Pregnancy ,Pregnancy Trimester, Second ,Pediatrics, Perinatology and Child Health ,Premature Rupture/therapy ,Humans ,Premature Birth ,Radiology, Nuclear Medicine and imaging ,Female ,Pregnancy Trimester ,Child ,Fetal Membranes ,Delivery ,Perinatal Mortality ,Randomized Controlled Trials as Topic - Abstract
Introduction: Midtrimester prelabor rupture of membranes (PROM) between 16 and 24 weeks of gestational age is a major obstetric complication with high rates of perinatal morbidity and mortality. Amnioinfusion has been proposed in women with midtrimester PROM to target oligohydramnios and subsequently enhance pulmonary development and perinatal outcomes. Material and Methods: The purpose of this study was to perform a systematic review and meta-analysis including all randomized clinical trials investigating amnioinfusion versus no intervention in women with PROM between 16+0 and 24+0 weeks of gestational age. Databases Central, Embase, Medline, ClinicalTrials.gov and references of identified articles were searched from inception of database to December 2021. The primary outcome was perinatal mortality. Secondary outcomes included neonatal, maternal, and long-term developmental outcomes as defined in the core outcome set for preterm birth studies. Summary measures were reported as pooled relative risk (RR) or mean difference with corresponding 95% confidence interval (CI). Results: Two studies (112 patients, 56 in the amnioinfusion group and 56 in the no intervention group) were included in this review. Pooled perinatal mortality was 66.1% (37/56) in the amnioinfusion group compared with 71.4% (40/56) in no intervention group (RR 0.92, 95% CI: 0.72–1.19). Other neonatal and maternal core outcomes were similar in both groups, although due to the relatively small number of events and wide CIs, there is a possibility that amnioinfusion can be associated with clinically important benefits and harms. Long-term healthy survival was seen in 35.7% (10/28) of children assessed for follow-up and treated with amnioinfusion versus 28.6% (8/28) after no intervention (RR 1.30, 95% CI: 0.47–3.60, “best case scenario”). Conclusions: Based on these findings, the benefits of amnioinfusion for midtrimester PROM
- Published
- 2022
12. Publisher Correction: Genome and transcriptome profiling of spontaneous preterm birth phenotypes
- Author
-
Juhi K. Gupta, Angharad Care, Laura Goodfellow, Zarko Alfirevic, Bertram Müller‑Myhsok, and Ana Alfirevic
- Subjects
Multidisciplinary ,Science ,Medicine - Published
- 2022
13. Maged et al. Am J Perinatol. 2020 Apr;37(5):491-49
- Author
-
Jim Thornton, Zarko Alfirevic, Vincenzo Berghella, Wessel Ganzevoort, Louise Kenny, Ben Mol, Francis Muriithi, Dwight Rouse, Andrew Shennan, Annika Strandell, Joris A.M. van der Post, Madelon van Wely, Obstetrics and Gynaecology, APH - Quality of Care, Amsterdam Reproduction & Development (AR&D), Center for Reproductive Medicine, APH - Methodology, APH - Personalized Medicine, and Obstetrics and gynaecology
- Subjects
Pediatrics, Perinatology and Child Health ,Obstetrics and Gynecology - Abstract
N/A.
- Published
- 2022
14. Amniocentesis and chorionic villus sampling
- Author
-
Gynaecologists, K Navaratnam, and Zarko Alfirevic
- Subjects
Gynecology ,medicine.medical_specialty ,medicine.diagnostic_test ,Obstetrics ,business.industry ,medicine ,MEDLINE ,Amniocentesis ,Obstetrics and Gynecology ,Chorionic villus sampling ,Guideline ,business - Published
- 2021
15. Maternal selenium levels and whole genome screen in recurrent spontaneous preterm birth population: A nested case control study
- Author
-
Nagendra Monangi, Julio Landero, Angharad Care, Ana Alfirevic, Joanne Chappell, Ge Zhang, Bertram Müller-Myhsok, Laura Goodfellow, Zarko Alfirevic, Andrew Sharp, Elizabeth Belling, Juhi K. Gupta, and Louis J. Muglia
- Subjects
medicine.medical_specialty ,Population ,Genome-wide association study ,Logistic regression ,Selenium ,Pregnancy ,Statistical significance ,Medicine ,Humans ,education ,Genetic association ,Nutrition ,education.field_of_study ,Models, Statistical ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,Preterm birth ,medicine.disease ,Prognosis ,Reproductive Medicine ,Case-Control Studies ,Nested case-control study ,Term Birth ,Premature Birth ,Female ,Genome wide association study ,business - Abstract
Objective: To establish if low maternal selenium (Se) was associated with sPTB in women with recurrent sPTB and identify genetic link with maternal Se levels. Design: Nested case-control study. Setting: Tertiary Maternity Hospital. Population: Plasma and whole blood from pregnant women with history of early sPTB/PPROM < 34 +0 and European ancestry were obtained at 20 weeks (range 15–24 weeks). ‘Cases’ were recurrent PTB/PPROM < 34 +0 weeks and term (≥37 +0) deliveries were classified as ‘high-risk controls.’ Women with previous term births and index birth ≥ 39 weeks were ‘low-risk controls’. Methods: Maternal plasma Se measured by ICP-MS was used as a continuous phenotype in a GWAS analysis. Se was added to a logistic regression model using PTB predictor variables. Main outcome measures: Maternal Se concentration, recurrent early sPTB/PPROM. Results: 53/177 high-risk women had a recurrent sPTB/PPROM < 34 +0weeks and were 2.7 times more likely to have a Se level < 83.3 ppm at 20weeks of pregnancy compared with low-risk term controls (n = 179), (RR 2.7, 95%CI 1.5–4.8; p =.001). One SNP from a non-coding region (FOXN3 intron variant, rs55793422) reached genome-wide significance level (p = 3.73E −08). Targeted analysis of Se gene variant did not show difference between preterm and term births. (χ 2 test, OR = 0.95; 95%CI = 0.59–1.56; p = 0.82). When Se levels were added to a clinical prediction model, only an additional 5% of cases (n = 3) and 0.6% (n = 1) of controls were correctly identified. Conclusions: Low plasma Se is associated with sPTB risk but is not sufficiently predictive at individual patient level. We did not find a genetic association between maternal Se levels and Se-related genes.
- Published
- 2021
16. The Induction with Foley OR Misoprostol (INFORM) Study dataset. A dataset of 602 women with hypertensive disease in pregnancy, in India, randomised to either Foley catheter or oral misoprostol for induction of labour
- Author
-
Andrew Weeks, Shuchita Mundle, Miroslava Ebringer, Jayashree Mulik, Hillary Bracken, Thomas R. Easterling, Kate Lightly, Zarko Alfirevic, Beverly Winikoff, Vaishali Khedikar, Paul Granby, Brian Faragher, Mark A. Turner, Alan Haycox, and Simon Leigh
- Subjects
Low income ,medicine.medical_specialty ,Science (General) ,Catheters ,Foley catheter ,QH301-705.5 ,Labour ,Hypertension in Pregnancy ,India ,wa_395 ,wa_310 ,Data Note ,General Biochemistry, Genetics and Molecular Biology ,Induction ,Q1-390 ,Pregnancy ,Oxytocics ,Humans ,Medicine ,wq_200 ,Labor, Induced ,Biology (General) ,Misoprostol ,Foley ,business.industry ,Obstetrics ,wj_100 ,Infant, Newborn ,General Medicine ,medicine.disease ,Mode of delivery ,Hypertensive disease ,Hypertension ,Female ,business ,Pre-eclampsia ,Dataset ,Cervical Ripening ,medicine.drug - Abstract
Objectives Induction of labour (IOL), or starting labour artificially, can be a lifesaving intervention for pregnant women and their babies, and rates are rising significantly globally. As rates increase, it becomes increasingly important to fully evaluate all available data, especially that from low income settings where the potential benefits and harms are greater. The goal of this paper is to describe the datasets collected as part of the Induction with Foley OR Misoprostol (INFORM) Study, a randomised trial comparing two of the recommended methods of cervical ripening for labour induction, oral misoprostol and Foley catheter, in women being induced for hypertension in pregnancy, at two sites in India during 2013–15. Data description This dataset includes comprehensive data on 602 women who underwent IOL for hypertensive disorders in pregnancy. Women were randomly assigned to cervical ripening with oral misoprostol or a transcervical Foley catheter in two government hospitals in India. The main dataset has 367 variables including monitoring during the induction of labour, medications administered, timing and mode of delivery, measures of neonatal morbidity and mortality, maternal mortality and morbidity, maternal satisfaction and health economic data. The dataset is anonymised and available on ReShare.
- Published
- 2021
17. Metabolic profiling of maternal serum of women a high-risk of spontaneous preterm birth using NMR and MGWAS approach
- Author
-
Bertram Müller-Myhsok, Marie M. Phelan, Juhi K. Gupta, Lu-Yun Lian, Ana Alfirevic, Angharad Care, Laura Goodfellow, and Zarko Alfirevic
- Subjects
Magnetic Resonance Spectroscopy ,Microarray ,Metabolite ,Physiology ,Biochemistry ,Molecular Bases of Health & Disease ,chemistry.chemical_compound ,Pregnancy ,Risk Factors ,biomarker discovery ,Genotype ,Medicine ,Prospective Studies ,Biomarker discovery ,Research Articles ,Oligonucleotide Array Sequence Analysis ,integumentary system ,mGWAS ,Genomics ,multiple omics ,Phenotype ,Cohort ,Metabolome ,Premature Birth ,Gestation ,Translational Science ,Female ,Analysis of variance ,Adult ,Biophysics ,Gestational Age ,Polymorphism, Single Nucleotide ,Risk Assessment ,Predictive Value of Tests ,Humans ,Metabolomics ,SNP ,Genetic Predisposition to Disease ,Systems Biology & Networks ,Lactic Acid ,TNF Receptor-Associated Factor 1/genetics ,Molecular Biology ,business.industry ,Premature Birth/blood ,Preterm birth ,Lactic Acid/blood ,Cell Biology ,TNF Receptor-Associated Factor 1 ,NMR ,Metabolism ,chemistry ,Case-Control Studies ,Neural Networks, Computer ,business ,Biomarkers ,Biomarkers/blood ,Genome-Wide Association Study - Abstract
Preterm birth (PTB) is a leading global cause of infant mortality. Risk factors include genetics, lifestyle choices and infection. Understanding the mechanism of PTB could aid the development of novel approaches to prevent PTB. This study aimed to investigate the metabolic biomarkers of PTB in early pregnancy and the association of significant metabolites with participant genotypes. Maternal sera collected at 16 and 20 weeks of gestation, from women who previously experienced PTB (high-risk) and women who did not (low-risk controls), were analysed using 1H nuclear magnetic resonance (NMR) metabolomics and genome-wide screening microarray. ANOVA and probabilistic neural network (PNN) modelling were performed on the spectral bins. Metabolomics genome-wide association (MGWAS) of the spectral bins and genotype data from the same participants was applied to determine potential metabolite-gene pathways. Phenylalanine, acetate and lactate metabolite differences between PTB cases and controls were obtained by ANOVA and PNN showed strong prediction at week 20 (AUC = 0.89). MGWAS identified several metabolite bins with strong genetic associations. Cis-eQTL analysis highlighted TRAF1 (involved in the inflammatory pathway) local to a non-coding SNP associated with lactate at week 20 of gestation. MGWAS of a well-defined cohort of participants highlighted a lactate-TRAF1 relationship that could potentially contribute to PTB.
- Published
- 2021
18. Plasma long-chain omega-3 fatty acid status and risk of recurrent early spontaneous preterm birth: a prospective observational study
- Author
-
Andrew Sharp, Laura Goodfellow, Ana Alfirevic, Jelena Ivandic, Zarko Alfirevic, Devender Roberts, Jane Harrold, Borna Poljak, Bertram Müller-Myhsok, Angharad Care, Maria Makrides, and Robert A. Gibson
- Subjects
Adult ,Relative risk reduction ,medicine.medical_specialty ,Population ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Risk Factors ,Fatty Acids, Omega-3 ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Omega 3 fatty acid ,education ,education.field_of_study ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,Obstetrics and Gynecology ,Prenatal Care ,General Medicine ,Odds ratio ,medicine.disease ,Eicosapentaenoic acid ,United Kingdom ,Dietary Supplements ,Premature Birth ,Term Birth ,Gestation ,Female ,business - Abstract
Introduction A 2018 Cochrane review found that omega-3 supplementation in pregnancy was associated with a risk reduction of early preterm birth of 0.58; prompting calls for universal supplementation. Recent analysis suggests the benefit may be confined to women with a low baseline omega-3 fatty acid status. However, the contemporary omega-3 fatty acid status of pregnant women in the UK is largely unknown. This is particularly pertinent for women with a previous preterm birth, in whom a small relative risk reduction would have a larger reduction of absolute risk. This study aimed to assess the omega-3 fatty acid status of a UK pregnant population and determine the association between the long-chain omega-3 fatty acids and recurrent spontaneous early preterm birth. Material and methods A total of 283 high-risk women with previous early preterm birth were recruited to the prospective observational study in Liverpool, UK. Additionally, 96 pregnant women with previous term births and birth ≥39+0 weeks in the index pregnancy provided a low-risk population sample. Within the high-risk group we assessed the odds ratio of recurrent early preterm birth compared with birth at ≥37+0 weeks of gestation according to plasma eicosapentaenoic acid plus docosahexaenoic acid (EPA+DHA) at 15-22 weeks of gestation. Results Our participants had low EPA+DHA; 62% (143/229) of women with previous preterm birth and 69% (68/96) of the population sample had levels within the lowest two quintiles of a previously published pregnancy cohort. We found no association between long-chain omega-3 status and recurrent early preterm birth (n = 51). The crude odds ratio of a recurrent event was 0.91 (95% CI 0.38-2.15, p = 0.83) for women in the lowest, compared with the highest three quintiles of EPA+DHA. Conclusions In the majority of our participants, levels of long-chain omega-3 were low; within the range that may benefit from supplementation. However, levels showed no association with risk of recurrent early spontaneous preterm birth. This could be because our population levels were too low to show benefit in being omega-3 "replete"; or else omega-3 levels may be of lesser importance in recurrent early preterm birth.
- Published
- 2021
19. Oral Misoprostol alone versus oral misoprostol followed by oxytocin for labour induction in women with hypertension in pregnancy (MOLI): protocol for a randomised controlled trial
- Author
-
Beverly Winikoff, Hillary Bracken, Brian Faragher, Simon Leigh, Thomas R. Easterling, Kate Lightly, Shuchita Mundle, Robbie Kerr, Mark A. Turner, Andrew Weeks, and Zarko Alfirevic
- Subjects
Augmentation of labour ,medicine.medical_specialty ,Hypertension in Pregnancy ,Reproductive medicine ,Administration, Oral ,India ,Oxytocin ,wa_310 ,law.invention ,Study Protocol ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Clinical Protocols ,Randomized controlled trial ,Pregnancy ,law ,Oral administration ,Oxytocics ,Pragmatic Clinical Trials as Topic ,Induction of labour ,medicine ,Humans ,Labor, Induced ,030212 general & internal medicine ,wq_300 ,Prostaglandin E1 ,Misoprostol ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,Obstetrics and Gynecology ,Hypertension, Pregnancy-Induced ,Gynecology and obstetrics ,medicine.disease ,qv_170 ,Hospitals ,Treatment Outcome ,chemistry ,RG1-991 ,Administration, Intravenous ,Female ,business ,Pre-eclampsia ,medicine.drug - Abstract
Background Every year approximately 30,000 women die from hypertensive disease in pregnancy. Magnesium sulphate and anti-hypertensives reduce morbidity, but delivery is the only cure. Low dose oral misoprostol, a prostaglandin E1 analogue, is a highly effective method for labour induction. Usually, once active labour has commenced, the misoprostol is replaced with an intravenous oxytocin infusion if ongoing stimulation is required. However, some studies have shown that oral misoprostol can be continued into active labour, a simpler and potentially more acceptable protocol for women. To date, these two protocols have never been directly compared. Methods This pragmatic, open-label, randomised trial will compare a misoprostol alone labour induction protocol with the standard misoprostol plus oxytocin protocol in three Indian hospitals. The study will recruit 520 pregnant women being induced for hypertensive disease in pregnancy and requiring augmentation after membrane rupture. Participants will be randomised to receive either further oral misoprostol 25mcg every 2 h, or titrated intravenous oxytocin. The primary outcome will be caesarean birth. Secondary outcomes will assess the efficacy of the induction process, maternal and fetal/neonatal complications and patient acceptability. This protocol (version 1.04) adheres to the SPIRIT checklist. A cost-effectiveness analysis, situational analysis and formal qualitative assessment of women’s experience are also planned. Discussion Avoiding oxytocin and continuing low dose misoprostol into active labour may have a number of benefits for both women and the health care system. Misoprostol is heat stable, oral medication and thus easy to store, transport and administer; qualities particularly desirable in low resource settings. An oral medication protocol requires less equipment (e.g. electronic infusion pumps) and may free up health care providers to assist with other aspects of the woman’s care. The simplicity of the protocol may also help to reduce human errors associated with the delivery of intravenous infusions. Finally, women may prefer to be mobile during labour and not restricted by an intravenous infusion. There is a need, therefore, to assess whether augmentation using oral misoprostol is superior clinically and economically to the standard protocol of intravenous oxytocin. Trial registration Clinical Trials.gov, NCT03749902, registered on 21st Nov 2018.
- Published
- 2021
20. Genome and transcriptome profiling of spontaneous preterm birth phenotypes
- Author
-
Juhi K. Gupta, Angharad Care, Laura Goodfellow, Zarko Alfirevic, Bertram Müller-Myhsok, and Ana Alfirevic
- Subjects
Receptors, Cell Surface/genetics ,Adult ,Fetal Membranes, Premature Rupture ,Science ,Quantitative Trait Loci ,Nerve Tissue Proteins ,Receptors, Cell Surface ,Article ,Pregnancy ,Genetics research ,Genetics ,Nerve Tissue Proteins/genetics ,Humans ,Forkhead Transcription Factors/genetics ,Multidisciplinary ,Gene Expression Profiling ,PPAR gamma/genetics ,Premature Birth/blood ,Pregnancy Outcome ,Fetal Membranes, Premature Rupture/blood ,Forkhead Transcription Factors ,Publisher Correction ,PPAR gamma ,MicroRNAs ,Medicine ,Premature Birth ,Female ,Systems biology ,Biomarkers/blood ,Biomarkers ,Genome-Wide Association Study - Abstract
Preterm birth (PTB) occurs before 37 weeks of gestation. Risk factors include genetics and infection/inflammation. Different mechanisms have been reported for spontaneous preterm birth (SPTB) and preterm birth following preterm premature rupture of membranes (PPROM). This study aimed to identify early pregnancy biomarkers of SPTB and PPROM from the maternal genome and transcriptome. Pregnant women were recruited at the Liverpool Women’s Hospital. Pregnancy outcomes were categorised as SPTB, PPROM (≤ 34 weeks gestation, n = 53), high-risk term (HTERM, ≥ 37 weeks, n = 126) or low-risk (no history of SPTB/PPROM) term (LTERM, ≥ 39 weeks, n = 188). Blood samples were collected at 16 and 20 weeks gestation from which, genome (UK Biobank Axiom array) and transcriptome (Clariom D Human assay) data were acquired. PLINK and R were used to perform genetic association and differential expression analyses and expression quantitative trait loci (eQTL) mapping. Several significant molecular signatures were identified across the analyses in preterm cases. Genome-wide significant SNP rs14675645 (ASTN1) was associated with SPTB whereas microRNA-142 transcript and PPARG1-FOXP3 gene set were associated with PPROM at week 20 of gestation and is related to inflammation and immune response. This study has determined genomic and transcriptomic candidate biomarkers of SPTB and PPROM that require validation in diverse populations.
- Published
- 2021
21. A prediction model for short-term neonatal outcomes in severe early-onset fetal growth restriction
- Author
-
Edward D. Johnstone, Jane Harrold, Peter von Dadelszen, Asma Khalil, Richard J. Jackson, Mark A. Turner, Philip N. Baker, Zarko Alfirevic, Louise C. Kenny, Christine Cornforth, Aris T. Papageorghiou, and Andrew Sharp
- Subjects
Adult ,Gestational hypertension ,Placental growth factor ,medicine.medical_specialty ,Ultrasonography, Prenatal ,Preeclampsia ,fetal growth restriction ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,medicine.artery ,medicine ,Birth Weight ,Humans ,030212 general & internal medicine ,Fetus ,Fetal Growth Retardation ,Models, Statistical ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,Infant, Newborn ,Pregnancy Outcome ,Obstetrics and Gynecology ,Umbilical artery ,medicine.disease ,Blood pressure ,Reproductive Medicine ,embryonic structures ,PlGF ratio [sFlt-1] ,Gestation ,Female ,stillbirth ,business ,Biomarkers - Abstract
BackgroundSevere early-onset fetal growth restriction (FGR) predisposes to fetal death, neonatal death, neonatal morbidity and neurodisability. The use of placental biomarkers has been proposed for risk stratification in pre-eclampsia, but they could be equally useful in fetal growth restriction in aiding management.ObjectiveTo determine the efficacy of angiogenic biomarkers at predicting adverse pregnancy outcome in severe early-onset fetal growth restriction.Study designThis is a secondary analysis of the multicentre, placebo-controlled STRIDER UK randomised controlled trial of singleton pregnancies with severe early-onset fetal growth restriction.Women with FGR pregnancies between 22+0 and 29+6 weeks of gestation were randomly assigned to receive either sildenafil 25 mg three times daily or placebo until 32+0 weeks’ gestation or delivery. We developed prediction models based upon maternal demographics (age, parity, blood pressure, preeclampsia, gestational hypertension), fetal biometric (estimated fetal weight) and Doppler measurements (Middle Cerebral Artery (MCA), Umbilical Artery (UA)) and maternal angiogenic biomarkers [placental growth factor (PlGF), soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt-1) and sFlt-1:PlGF ratio) using both univariate and multivariate analysis.ResultsA complete data set was available for 105 of 135 randomised women. Multivariate regression analysis identified estimated fetal weight (EFW) and sFlt-1:PlGF as independent predictors of livebirth (EFW OR: 1.01 (1.008, 1.021); p ConclusionsIn severe early-onset FGR pregnancies livebirth and overall survival can be predicted using a model involving EFW and sFlt-1:PlGF ratio. This model require validation in a larger cohort but may allow informed decision making about pregnancy management, especially in previable cases.
- Published
- 2019
22. ISUOG Practice Guidelines: ultrasound assessment of fetal biometry and growth
- Author
-
Aris T. Papageorghiou, F. Figueras, R. Napolitano, Alexandros Sotiriadis, Laurent Salomon, Julien Stirnemann, George S. H. Yeo, Russell L. Deter, F. da Silva Costa, Ants Toi, Zarko Alfirevic, Wesley Lee, Asma Khalil, Phyllis Glanc, and Tullio Ghi
- Subjects
medicine.medical_specialty ,Biometry ,Amniotic fluid ,medicine.medical_treatment ,Intrauterine growth restriction ,Crown-Rump Length ,Ultrasonography, Prenatal ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Fetal macrosomia ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Societies, Medical ,Crown-rump length ,Fetus ,Fetal Growth Retardation ,030219 obstetrics & reproductive medicine ,Assisted reproductive technology ,Radiological and Ultrasound Technology ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,Gestational age ,General Medicine ,medicine.disease ,Reproductive Medicine ,Practice Guidelines as Topic ,Female ,business - Abstract
INTRODUCTION These Guidelines aim to describe appropriate assessment of fetal biometry and diagnosis of fetal growth disorders. These disorders consist mainly of fetal growth restriction (FGR), also referred to as intrauterine growth restriction (IUGR) and often associated with small‐for‐gestational age (SGA), and large‐for‐gestational age (LGA), which may lead to fetal macrosomia; both have been associated with a variety of adverse maternal and perinatal outcomes. Screening for, and adequate management of, fetal growth abnormalities are essential components of antenatal care, and fetal ultrasound plays a key role in assessment of these conditions. The fetal biometric parameters measured most commonly are biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur diaphysis length (FL). These biometric measurements can be used to estimate fetal weight (EFW) using various different formulae1. It is important to differentiate between the concept of fetal size at a given timepoint and fetal growth, the latter being a dynamic process, the assessment of which requires at least two ultrasound scans separated in time. Maternal history and symptoms, amniotic fluid assessment and Doppler velocimetry can provide additional information that may be used to identify fetuses at risk of adverse pregnancy outcome. Accurate estimation of gestational age is a prerequisite for determining whether fetal size is appropriate‐for‐gestational age (AGA). Except for pregnancies arising from assisted reproductive technology, the date of conception cannot be determined precisely. Clinically, most pregnancies are dated by the last menstrual period, though this may sometimes be uncertain or unreliable. Therefore, dating pregnancies by early ultrasound examination at 8–14 weeks, based on measurement of the fetal crown–rump length (CRL), appears to be the most reliable method to establish gestational age. Once the CRL exceeds 84 mm, HC should be used for pregnancy dating2–4. HC, with or without FL, can be used for estimation of gestational age from the mid‐trimester if a first‐trimester scan is not available and the menstrual history is unreliable. When the expected delivery date has been established by an accurate early scan, subsequent scans should not be used to recalculate the gestational age1. Serial scans can be used to determine if interval growth has been normal. In these Guidelines, we assume that the gestational age is known and has been determined as described above, the pregnancy is singleton and the fetal anatomy is normal. Details of the grades of recommendation used in these Guidelines are given in Appendix 1. Reporting of levels of evidence is not applicable to these Guidelines.Pautas de ISUOG para la práctica: evaluación ecográfica de la biometría y el crecimiento fetal INTRODUCCIÓN: El objetivo de estas Pautas es describir la evaluación adecuada de la biometría fetal y el diagnóstico de los trastornos del crecimiento fetal. Estos trastornos consisten principalmente en la restricción del crecimiento fetal (RCF), también conocida como restricción del crecimiento intrauterino (RCIU), que a menudo está asociada con un tamaño pequeño para la edad gestacional (PEG) o grande para la edad gestacional (GEG), que pueden dar lugar a la macrosomía fetal; ambos se han asociado con una variedad de resultados maternos y perinatales adversos. La detección y el tratamiento adecuado de las anomalías del crecimiento fetal son componentes esenciales de la atención prenatal, y la ecografía fetal desempeña un papel fundamental en la evaluación de estas afecciones. Los parámetros biométricos fetales medidos con mayor frecuencia son (todas las siglas procedentes del inglés) el diámetro biparietal (BPD), el perímetro cefálico (HC), el perímetro abdominal (AC) y la longitud de la diáfisis del fémur (FL). Estas mediciones biométricas se pueden utilizar para estimar el peso del feto (PEF) mediante fórmulas diferentesISUOG实践指南:胎儿生物测量与生长的超声评估 引言: 本指南旨在描述胎儿生物测量的正确评估及胎儿生长障碍的诊断。这些疾病主要包括又称为宫内生长受限(IUGR)且往往与小于胎龄(SGA)有关的胎儿生长受限(FGR),以及可能导致胎儿巨大的大于胎龄(LGA)。这两种疾病都与各种孕产期围产期不良结局有关。胎儿生长异常的筛查和适当处理是产前保健的重要组成部分,胎儿超声检测在这些疾病的评估中起着关键作用。最常测量的胎儿生物特征参数有双顶径(BPD)、头围(HC)、腹围(AC)和股骨骨干长度(FL)。可以根据这些生物特征测量值,运用各种不同的公式估算胎儿体重(EFW)。
- Published
- 2019
23. Does water birth affect the risk of obstetric anal sphincter injury? Development of a prognostic model
- Author
-
Helen Louise Preston, Gillian Fowler, Zarko Alfirevic, and Steven Lane
- Subjects
Adult ,Male ,Multivariate statistics ,medicine.medical_specialty ,Multivariate analysis ,Urology ,030232 urology & nephrology ,Anal Canal ,Black People ,Risk Assessment ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Pregnancy ,Risk Factors ,Humans ,Medicine ,Natural Childbirth ,Retrospective Studies ,Water birth ,Univariate analysis ,Models, Statistical ,030219 obstetrics & reproductive medicine ,business.industry ,Vaginal delivery ,Obstetrics ,Obstetrics and Gynecology ,Retrospective cohort study ,Odds ratio ,United Kingdom ,Confidence interval ,Parity ,Wounds and Injuries ,Female ,business ,Forecasting - Abstract
Obstetric anal sphincter injury (OASI) is a significant complication of vaginal delivery. Water birth has become a popular preference for women giving birth in the UK, however, there is limited data on the risk of OASI following water birth. Our aim was to assess OASI risk in low-risk women giving birth in water without medical intervention compared with on land and to create a prognostic model for OASI prediction. This was a retrospective study of 15,734 low-risk women giving birth by spontaneous vaginal delivery between January 2008 and October 2014 in a midwifery-led unit (MLU). Patient factors and delivery data were analysed to identify differences between water and land births. Univariate analysis determined factors that statistically predicted OASI and was then used to create multivariate analysis. Significant multivariate factors were used to create a prognostic model to predict likelihood of OASI. OASI rates were 1.6% on land and 3.3% in water [odds ratio (OR) 2.10, 95% confidence interval (CI) 1.5–2.94). Multivariate analysis confirmed water birth, ethnicity and parity as independent risk factors for OASI (adjusted OR water birth: 1.77 (CI 1.25–2.51). Our prognostic model showed Black and Asian primigravidae following water birth had the highest risk of OASI and white multiparae on land the lowest. This study of comparable low-risk women shows an increased risk of OASI following water birth compared with land birth. Use of this prognostic model will help women determine their risk of OASI following birth in water or on land.
- Published
- 2019
24. Screening and management of the small for gestational age fetus in the UK: A survey of practice
- Author
-
Andrew Sharp, Zarko Alfirevic, Umber Agarwal, and C. Duong
- Subjects
Adult ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Gestational Age ,Ultrasonography, Prenatal ,Umbilical Arteries ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,medicine.artery ,Screening method ,medicine ,Humans ,030212 general & internal medicine ,Fundal height ,reproductive and urinary physiology ,Response rate (survey) ,Small for gestational age fetus ,Fetus ,Fetal Growth Retardation ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,Infant, Newborn ,Obstetrics and Gynecology ,Ultrasonography, Doppler ,Umbilical artery ,medicine.disease ,United Kingdom ,female genital diseases and pregnancy complications ,Fetal Weight ,Reproductive Medicine ,Health Care Surveys ,Infant, Small for Gestational Age ,Small for gestational age ,Gestation ,Female ,business - Abstract
Background Antenatal detection of the small for gestational (SGA) fetus has become an important indicator of quality of antenatal care in the UK. This has been driven by a desire to reduce stillbirth in this at risk group. Methods We conducted a postal survey of 187 NHS consultant units within the UK to determine what the current practice for the detection and subsequent management of the suspected SGA fetus was following the guidance from the Royal College of Obstetricians and Gynaecologists (RCOG) in 2013. Results The survey was performed in 3 rounds between 2016 and 2017 with a response rate of 65%. 85% of units assessed risk factors for SGA at booking. 81% of units used a customized symphysis fundal height (SFH) chart to screen for SGA with 95% of them using a cut off of
- Published
- 2018
25. Vaginal bacterial load in the second trimester is associated with early preterm birth recurrence: a nested case-control study
- Author
-
Jhhm van de Wijgert, Jelena Ivandic, Devender Roberts, Angharad Care, Christina Bronowski, Borna Poljak, Alistair C. Darby, Bertram Müller-Myhsok, Ana Alfirevic, Marijn C. Verwijs, Zarko Alfirevic, A C Gill, Laura Goodfellow, and Andrew Sharp
- Subjects
Adult ,Fetal Membranes, Premature Rupture ,medicine.medical_specialty ,Gestational Age ,Young Adult ,Pregnancy ,RNA, Ribosomal, 16S ,Statistical significance ,Lactobacillus ,Lactobacillus iners ,medicine ,Humans ,Rupture of membranes ,Lactobacillus crispatus ,biology ,business.industry ,Obstetrics ,Microbiota ,Obstetrics and Gynecology ,Odds ratio ,medicine.disease ,biology.organism_classification ,Bacterial Load ,Confidence interval ,Case-Control Studies ,Pregnancy Trimester, Second ,Vagina ,Nested case-control study ,Premature Birth ,Gestation ,Female ,business ,Dysbiosis - Abstract
ObjectiveTo assess the association between vaginal microbiome (VMB) composition and recurrent early spontaneous preterm birth (sPTB)/preterm prelabour rupture of membranes (PPROM).DesignNested case-control study.SettingUK tertiary referral hospital.SampleHigh-risk women with previous sPTB/PPROM +0 weeks gestation who had a recurrence (n=22) or delivered at ≥37+0 weeks without PPROM (n=87).MethodsVaginal swabs collected between 15-22 weeks gestation were analysed by 16S rRNA gene sequencing and 16S quantitative PCR.Main outcome measureRecurrent early sPTB/PPROM.Results28/109 high-risk women had anaerobic vaginal dysbiosis, with the remainder dominated by lactobacilli (L. iners 36/109, L. crispatus 23/109, or other 22/109). VMB type, diversity, and stability were not associated with recurrence. Women with a recurrence, compared to those without, had a higher median vaginal bacterial load (8.64 vs. 7.89 log10 cells/μl, adjusted odds ratio (aOR)=1.90, 95% confidence interval (CI)=1.01-3.56, p=0.047) and estimated Lactobacillus concentration (8.59 vs. 7.48 log10 cells/μl, aOR=2.35, CI=1.20-4.61, p=0.013). A higher recurrence risk was associated with higher median bacterial loads for each VMB type after stratification, although statistical significance was reached only for L. iners-domination (aOR=3.44, CI=1.06-11.15, p=0.040). Women with anaerobic dysbiosis or L. iners-domination had a higher median vaginal bacterial load than women with a VMB dominated by L. crispatus or other lactobacilli (8.54, 7.96, 7.63, and 7.53 log10 cells/μl, respectively).ConclusionsVaginal bacterial load is associated with early sPTB/PPROM recurrence. Domination by lactobacilli other than L. iners may protect women from developing high bacterial loads. Future PTB studies should quantify vaginal bacteria and yeasts.FundingWellbeing of Women, London, UKTweetable abstractIncreased vaginal bacterial load in the second trimester may be associated with recurrent early spontaneous preterm birth.
- Published
- 2021
26. Uterotonic agents for first-line treatment of postpartum haemorrhage: a network meta-analysis
- Author
-
Malcolm J Price, Shireen Meher, G Justus Hofmeyr, Ioannis D. Gallos, Andrew Weeks, Olufemi T Oladapo, Arri Coomarasamy, Fernando Althabe, Mariana Widmer, Argyro Papadopoulou, Zarko Alfirevic, Ahmet Metin Gülmezoglu, Eleanor Thomas, William R Parry Smith, Aurelio Tobias, and Joshua P. Vogel
- Subjects
medicine.medical_specialty ,Blood transfusion ,medicine.medical_treatment ,Network Meta-Analysis ,Uterotonic ,Oxytocin ,03 medical and health sciences ,0302 clinical medicine ,Bias ,Pregnancy ,Oxytocics ,medicine ,Confidence Intervals ,Childbirth ,Humans ,Pharmacology (medical) ,Ergometrine ,Blood Transfusion ,030212 general & internal medicine ,Ergonovine ,Misoprostol ,Randomized Controlled Trials as Topic ,business.industry ,Obstetrics ,Postpartum Hemorrhage ,medicine.disease ,Clinical trial ,Relative risk ,Maternal death ,Drug Therapy, Combination ,Female ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
BackgroundPostpartum haemorrhage (PPH), defined as a blood loss of 500 mL or more after birth, is the leading cause of maternal death worldwide. The World Health Organization (WHO) recommends that all women giving birth should receive a prophylactic uterotonic agent. Despite the routine administration of a uterotonic agent for prevention, PPH remains a common complication causing one-quarter of all maternal deaths globally. When prevention fails and PPH occurs, further administration of uterotonic agents as 'first-line' treatment is recommended. However, there is uncertainty about which uterotonic agent is best for the 'first-line' treatment of PPH.ObjectivesTo identify the most effective uterotonic agent(s) with the least side-effects for PPH treatment, and generate a meaningful ranking among all available agents according to their relative effectiveness and side-effect profile.Search methodsWe searched the Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (5 May 2020), and the reference lists of all retrieved studies.Selection criteriaAll randomised controlled trials or cluster-randomised trials comparing the effectiveness and safety of uterotonic agents with other uterotonic agents for the treatment of PPH were eligible for inclusion.Data collection and analysisTwo review authors independently assessed all trials for inclusion, extracted data and assessed each trial for risk of bias. Our primary outcomes were additional blood loss of 500 mL or more after recruitment to the trial until cessation of active bleeding and the composite outcome of maternal death or severe morbidity. Secondary outcomes included blood loss-related outcomes, morbidity outcomes, and patient-reported outcomes. We performed pairwise meta-analyses and indirect comparisons, where possible, but due to the limited number of included studies, we were unable to conduct the planned network meta-analysis. We used the GRADE approach to assess the certainty of evidence.Main resultsSeven trials, involving 3738 women in 10 countries, were included in this review. All trials were conducted in hospital settings. Randomised women gave birth vaginally, except in one small trial, where women gave birth either vaginally or by caesarean section. Across the seven trials (14 trial arms) the following agents were used: six trial arms used oxytocin alone; four trial arms used misoprostol plus oxytocin; three trial arms used misoprostol; one trial arm used Syntometrine® (oxytocin and ergometrine fixed-dose combination) plus oxytocin infusion. Pairwise meta-analysis of two trials (1787 participants), suggests that misoprostol, as first-line treatment uterotonic agent, probably increases the risk of blood transfusion (risk ratio (RR) 1.47, 95% confidence interval (CI) 1.02 to 2.14, moderate-certainty) compared with oxytocin. Low-certainty evidence suggests that misoprostol administration may increase the incidence of additional blood loss of 1000 mL or more (RR 2.57, 95% CI 1.00 to 6.64). The data comparing misoprostol with oxytocin is imprecise, with a wide range of treatment effects for the additional blood loss of 500 mL or more (RR 1.66, 95% CI 0.69 to 4.02, low-certainty), maternal death or severe morbidity (RR 1.98, 95% CI 0.36 to 10.72, low-certainty, based on one study n = 809 participants, as the second study had zero events), and the use of additional uterotonics (RR 1.30, 95% CI 0.57 to 2.94, low-certainty). The risk of side-effects may be increased with the use of misoprostol compared with oxytocin: vomiting (2 trials, 1787 participants, RR 2.47, 95% CI 1.37 to 4.47, high-certainty) and fever (2 trials, 1787 participants, RR 3.43, 95% CI 0.65 to 18.18, low-certainty). According to pairwise meta-analysis of four trials (1881 participants) generating high-certainty evidence, misoprostol plus oxytocin makes little or no difference to the use of additional uterotonics (RR 0.99, 95% CI 0.94 to 1.05) and to blood transfusion (RR 0.95, 95% CI 0.77 to 1.17) compared with oxytocin. We cannot rule out an important benefit of using the misoprostol plus oxytocin combination over oxytocin alone, for additional blood loss of 500 mL or more (RR 0.84, 95% CI 0.66 to 1.06, moderate-certainty). We also cannot rule out important benefits or harms for additional blood loss of 1000 mL or more (RR 0.76, 95% CI 0.43 to 1.34, moderate-certainty, 3 trials, 1814 participants, one study reported zero events), and maternal mortality or severe morbidity (RR 1.09, 95% CI 0.35 to 3.39, moderate-certainty). Misoprostol plus oxytocin increases the incidence of fever (4 trials, 1866 participants, RR 3.07, 95% CI 2.62 to 3.61, high-certainty), and vomiting (2 trials, 1482 participants, RR 1.85, 95% CI 1.16 to 2.95, high-certainty) compared with oxytocin alone. For all outcomes of interest, the available evidence on the misoprostol versus Syntometrine® plus oxytocin combination was of very low-certainty and these effects remain unclear. Although network meta-analysis was not performed, we were able to compare the misoprostol plus oxytocin combination with misoprostol alone through the common comparator of oxytocin. This indirect comparison suggests that the misoprostol plus oxytocin combination probably reduces the risk of blood transfusion (RR 0.65, 95% CI 0.42 to 0.99, moderate-certainty) and may reduce the risk of additional blood loss of 1000 mL or more (RR 0.30, 95% CI 0.10 to 0.89, low-certainty) compared with misoprostol alone. The combination makes little or no difference to vomiting (RR 0.75, 95% CI 0.35 to 1.59, high-certainty) compared with misoprostol alone. Misoprostol plus oxytocin compared to misoprostol alone are compatible with a wide range of treatment effects for additional blood loss of 500 mL or more (RR 0.51, 95% CI 0.20 to 1.26, low-certainty), maternal mortality or severe morbidity (RR 0.55, 95% CI 0.07 to 4.24, low-certainty), use of additional uterotonics (RR 0.76, 95% CI 0.33 to 1.73, low-certainty), and fever (RR 0.90, 95% CI 0.17 to 4.77, low-certainty).Authors' conclusionsThe available evidence suggests that oxytocin used as first-line treatment of PPH probably is more effective than misoprostol with less side-effects. Adding misoprostol to the conventional treatment of oxytocin probably makes little or no difference to effectiveness outcomes, and is also associated with more side-effects. The evidence for most uterotonic agents used as first-line treatment of PPH is limited, with no evidence found for commonly used agents, such as injectable prostaglandins, ergometrine, and Syntometrine®.
- Published
- 2020
27. The PLANES study: a protocol for a randomised controlled feasibility study of the placental growth factor (PlGF) blood test-informed care versus standard care alone for women with a small for gestational age fetus at or after 32 + 0 weeks’ gestation
- Author
-
Emily Benbow, Joanna Gent, Christine Cornforth, Andrew Sharp, Jane Harrold, Louise C. Kenny, Kerry Woolfall, Sian Bullough, Zarko Alfirevic, Richard J. Jackson, Alexander E. P. Heazell, and Lazaros Andronis
- Subjects
Fetal growth restriction (FGR) ,medicine.medical_specialty ,Placenta ,Medicine (miscellaneous) ,Intrauterine growth restriction ,Soluble fms-like tyrosine kinase ,law.invention ,03 medical and health sciences ,Study Protocol ,0302 clinical medicine ,Randomized controlled trial ,law ,Placental growth factor ,medicine ,Blood test ,030212 general & internal medicine ,reproductive and urinary physiology ,lcsh:R5-920 ,Pregnancy ,Fetus ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,Obstetrics ,business.industry ,medicine.disease ,Regimen ,Small for gestational age (SGA) ,Gestation ,Small for gestational age ,RG ,lcsh:Medicine (General) ,business - Abstract
Background Stillbirth remains a major concern across the globe and in some high-resource countries, such as the UK; efforts to reduce the rate have achieved only modest reductions. One third of stillborn babies are small for gestational age (SGA), and these pregnancies are also at risk of neonatal adverse outcomes and lifelong health problems, especially when delivered preterm. Current UK clinical guidance advocates regular monitoring and early term delivery of the SGA fetus; however, the most appropriate regimen for surveillance of these babies remains unclear and often leads to increased intervention for a large number of these women. This pilot trial will determine the feasibility of a large-scale trial refining the risk of adverse pregnancy outcome in SGA pregnancies using biomarkers of placental function sFlt-1/PlGF, identifying and intervening in only those deemed at highest risk of stillbirth. Methods PLANES is a randomised controlled feasibility study of women with an SGA fetus that will be conducted at two tertiary care hospitals in the UK. Once identified on ultrasound, women will be randomised into two groups in a 3:1 ratio in favour of sFlt-1/PlGF ratio led management vs standard care. Women with an SGA fetus and a normal sFlt-1/PlGF ratio will have a repeat ultrasound and sFlt-1/PlGF ratio every 2 weeks with planned birth delayed until 40 weeks. In those women with an SGA fetus and an abnormal sFlt-1/PlGF ratio, we will offer birth from 37 weeks or sooner if there are other concerning features on ultrasound. Women assigned to standard care will have an sFlt-1/PlGF ratio taken, but the results will be concealed from the clinical team, and the woman’s pregnancy will be managed as per the local NHS hospital policy. This integrated mixed method study will also involve a health economic analysis and a perspective work package exploring trial feasibility through interviews and questionnaires with participants, their partners, and clinicians. Discussion Our aim is to determine feasibility through the assessment of our ability to recruit and retain participants to the study. Results from this pilot study will inform the design of a future large randomised controlled trial that will be adequately powered for adverse pregnancy outcome. Such a study would provide the evidence needed to guide future management of the SGA fetus. Trial registration ISRCTN58254381. Registered on 4 July 2019
- Published
- 2020
28. Home versus inpatient induction of labour for improving birth outcomes
- Author
-
Alfred Osoti, Gillian Ml Gyte, Zarko Alfirevic, Vicky Nogueira Pileggi, Rachel Plachcinski, and Elaine Finucane
- Subjects
medicine.medical_specialty ,Neonatal intensive care unit ,Dinoprostone ,law.invention ,Catheterization ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,Randomized controlled trial ,law ,Pregnancy ,Oxytocics ,Ambulatory Care ,Medicine ,Childbirth ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Labor, Induced ,Randomized Controlled Trials as Topic ,business.industry ,Obstetrics ,Cesarean Section ,Infant, Newborn ,Pregnancy Outcome ,Length of Stay ,Hospitalization ,Neonatal infection ,Patient Satisfaction ,Meta-analysis ,Delayed-Action Preparations ,Observational study ,Female ,Patient Safety ,RG ,business ,030217 neurology & neurosurgery ,Cohort study ,Cervical Ripening - Abstract
Background\ud The setting in which induction of labour takes place (home or inpatient) is likely to have implications for safety, women's experiences and costs.\ud \ud Home induction may be started at home with the subsequent active phase of labour happening either at home or in a healthcare facility (hospital, birth centre, midwifery‐led unit). More commonly, home induction starts in a healthcare facility, then the woman goes home to await the start of labour. Inpatient induction takes place in a healthcare facility where the woman stays while awaiting the start of labour.\ud \ud Objectives\ud To assess the effects on neonatal and maternal outcomes of third trimester home induction of labour compared with inpatient induction using the same method of induction.\ud \ud Search methods\ud For this update, we searched the Cochrane Pregnancy and Childbirth Group's Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (31 January 2020)), and reference lists of retrieved studies.\ud \ud Selection criteria\ud Published and unpublished randomised controlled trials (RCTs) in which home and inpatient settings for induction have been compared. We included conference abstracts but excluded quasi‐randomised trials and cross‐over studies.\ud \ud Data collection and analysis\ud Two review authors independently assessed study reports for inclusion. Two review authors carried out data extraction and assessment of risk of bias independently. GRADE assessments were checked by a third review author.\ud \ud Main results\ud We included seven RCTs, six of which provided data on 1610 women and their babies. Studies were undertaken between 1998 and 2015, and all were in high‐ or upper‐middle income countries. Most women were induced for post dates. Three studies reported government funding, one reported no funding and three did not report on their funding source. Most GRADE assessments gave very low‐certainty evidence, downgrading mostly for high risk of bias and serious imprecision.\ud \ud 1. Home compared to inpatient induction with vaginal prostaglandin E (PGE) (two RCTs, 1028 women and babies; 1022 providing data).\ud \ud Although women's satisfaction may be slightly better in home settings, the evidence is very uncertain (mean difference (MD) 0.16, 95% confidence interval (CI) ‐0.02 to 0.34, 1 study, 399 women), very low‐certainty evidence.\ud \ud There may be little or no difference between home and inpatient induction for other primary outcomes, with all evidence being very low certainty:\ud \ud ‐ spontaneous vaginal birth (average risk ratio (RR) [aRR] 0.91, 95% CI 0.69 to 1.21, 2 studies, 1022 women, random‐effects method);\ud \ud ‐ uterine hyperstimulation (RR 1.19, 95% CI 0.40 to 3.50, 1 study, 821 women);\ud \ud ‐ caesarean birth (RR 1.01, 95% CI 0.81 to 1.28, 2 studies, 1022 women);\ud \ud ‐ neonatal infection (RR 1.29, 95% CI 0.59 to 2.82, 1 study, 821 babies);\ud \ud ‐ admission to neonatal intensive care unit (NICU) (RR 1.20, 95% CI 0.50 to 2.90, 2 studies, 1022 babies).\ud \ud Studies did not report serious neonatal morbidity or mortality.\ud \ud 2. Home compared to inpatient induction with controlled release PGE (one RCT, 299 women and babies providing data).\ud \ud There was no information on whether the questionnaire on women's satisfaction with care used a validated instrument, but the findings presented showed no overall difference in scores.\ud \ud We found little or no difference between the groups for other primary outcomes, all also being very low‐certainty evidence:\ud \ud ‐ spontaneous vaginal birth (RR 0.94, 95% CI 0.77 to 1.14, 1 study, 299 women);\ud \ud ‐ uterine hyperstimulation (RR 1.01, 95% CI 0.51 to 1.98, 1 study, 299 women);\ud \ud ‐ caesarean births (RR 0.95, 95% CI 0.64 to 1.42, 1 study, 299 women);\ud \ud ‐ admission to NICU (RR 1.38, 0.57 to 3.34, 1 study, 299 babies).\ud \ud The study did not report on neonatal infection nor serious neonatal morbidity or mortality.\ud \ud 3. Home compared to inpatient induction with balloon or Foley catheter (four RCTs; three studies, 289 women and babies providing data).\ud \ud It was again unclear whether questionnaires reporting women's experiences/satisfaction with care were validated instruments, with one study (48 women, 69% response rate) finding women were similarly satisfied.\ud \ud Home inductions may reduce the number of caesarean births, but the data are also compatible with a slight increase and are of very low‐certainty (RR 0.64, 95% CI 0.41 to 1.01, 2 studies, 159 women).\ud \ud There was little or no difference between the groups for other primary outcomes with all being very low‐certainty evidence:\ud \ud ‐ spontaneous vaginal birth (RR 1.04, 95% CI 0.54 to 1.98, 1 study, 48 women):\ud \ud ‐ uterine hyperstimulation (RR 0.45, 95% CI 0.03 to 6.79, 1 study, 48 women);\ud \ud ‐ admission to NICU (RR 0.37, 95% CI 0.07 to 1.86, 2 studies, 159 babies).\ud \ud There were no serious neonatal infections nor serious neonatal morbidity or mortality in the one study (involving 48 babies) assessing these outcomes.\ud \ud Authors' conclusions\ud Data on the effectiveness, safety and women's experiences of home versus inpatient induction of labour are limited and of very low‐certainty. Given that serious adverse events are likely to be extremely rare, the safety data are more likely to come from very large observational cohort studies rather than relatively small RCTs.
- Published
- 2020
29. Retracted papers are only the tip of the iceberg of untrustworthy evidence
- Author
-
Zarko Alfirevic
- Subjects
Obstetrics ,Paleontology ,Biomedical Research ,business.industry ,Scientific Misconduct ,Medicine ,General Medicine ,business ,Iceberg - Published
- 2020
30. Skeletal abnormalities secondary to antenatal etidronate treatment for suspected generalised arterial calcification of infancy
- Author
-
Renuka Ramakrishnan, Caren Landes, Neha Agarwal, Umber Agarwal, M Zulf Mughal, Zarko Alfirevic, Joyce Su Ling Lim, and Musa Kaleem
- Subjects
0301 basic medicine ,medicine.medical_specialty ,lcsh:Diseases of the musculoskeletal system ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Antenatal ,Orthopedics and Sports Medicine ,Pregnancy ,Tricuspid valve ,medicine.diagnostic_test ,business.industry ,Hypophosphatasia ,Bisphosphonates ,Bisphosphonate ,medicine.disease ,Arterial calcification ,medicine.anatomical_structure ,Angiography ,Cardiology ,Gestation ,030101 anatomy & morphology ,GACI ,lcsh:RC925-935 ,business ,Calcification - Abstract
Background Generalised arterial calcification of infancy (GACI) is a rare disorder characterised by the deposition of hydroxyapatite crystals within the vessel walls. It is associated with a high mortality rate. Bisphosphonates have been used with some success in the treatment of GACI. However, there is a paucity of data on the antenatal use of bisphosphonates for GACI. In this paper, we report development of the skeletal changes suggestive of hypophosphatasia (HPP) in an infant with GACI, whose mother was treated with etidronate during pregnancy. Case report A Caucasian infant boy had a suspected antenatal diagnosis of GACI based on the findings suggestive of calcification of the annulus of the tricuspid valve and wall of the right ventricular (RV) outflow tract and main pulmonary artery on foetal echocardiography and the genetic analysis which showed a pathogenic heterozygous mutation in ABCC6. Based on these findings, mother was started on etidronate treatment from 26 weeks of gestation. A healthy male baby was delivered at 38 weeks of gestation. Initial postnatal echocardiogram on day 1 of life was normal with good biventricular function; subtle changes suggestive of microcalcifications were detected on the CT angiography. Serum calcium, phosphate, alkaline phosphatase and renal profile were normal. Further, the serum inorganic pyrophosphate (PPi) level was significantly low. Skeletal changes suggestive of HPP were seen on the radiographs. The baby developed cardiac dysfunction on day 4 of life with evidence of ischaemic changes on electrocardiogram (ECG). Treatment with etidronate was started in view of probable evolving coronary calcifications. Despite treatment with cardiac supportive measures and bisphosphonate, he succumbed to death in the third week of life. Discussion We believe, this is the first report of skeletal changes suggestive of HPP, arising secondary to antenatal etidronate (first generation bisphosphonate) used for the treatment of suspected GACI due to a heterozygous ABCC6 mutation., Highlights • Generalized arterial calcification of infancy is amineralisation defect due to low plasma inorganic pyrophosphate (PPi) . • Antenatal treatment with etidronate was found to be associated with skeletal changes suggestive of hypophosphatasia (HPP). • A contrasting radiographic feature of PPi excess state (HPP) is noted in the presence of a PPi deficient disease (GACI). • A close monitoring is warranted with an antenatal use of etidronate.
- Published
- 2020
31. Invasive Diagnostic Procedures in Obstetrics
- Author
-
Asim Kurjak and Zarko Alfirevic
- Subjects
medicine.medical_specialty ,Obstetrics ,business.industry ,medicine ,business - Published
- 2020
32. Doppler Ultrasound in the Assessment of Fetal and Maternal Circulation
- Author
-
Zarko Alfirevic and Asim Kurjak
- Subjects
medicine.medical_specialty ,Fetus ,Circulation (fluid dynamics) ,business.industry ,Internal medicine ,medicine ,Cardiology ,Doppler ultrasound ,business - Published
- 2020
33. Trial sequential analysis: useful or useless?
- Author
-
Simon Gates and Zarko Alfirevic
- Subjects
business.industry ,Cerebral Palsy ,Infant, Newborn ,Obstetrics and Gynecology ,Infant ,Machine learning ,computer.software_genre ,Magnesium Sulfate ,Double-Blind Method ,Pregnancy ,Medicine ,Humans ,Female ,Artificial intelligence ,business ,computer - Published
- 2020
34. Preterm birth
- Author
-
Angharad Care and Zarko Alfirevic
- Abstract
This chapter discusses the epidemiology, prediction, prevention, and management of spontaneous preterm birth. Preterm birth is usually defined as delivery at any gestation before 37 completed weeks of pregnancy (+0 weeks
- Published
- 2020
35. Association of Maternal Prenatal Selenium Concentration and Preterm Birth: A Multi-Country Meta-Analysis
- Author
-
Rasheda Khanam, Bellington Vwalika, Abdullah Al Mahmud, M Munirul Islam, Jeffrey C. Murray, Abdullah H Baqui, Fyezah Jehan, Yue-Mei Fan, Anisur Rahman, Joan T. Price, Sayedur Rahman, Angharad Care, Fahad Aftab, Patrick Musonda, Julio Landero, Saikat Deb, Nagendra Monangi, Sunil Sazawal, Cathrine Hoyo, Mikko Hallman, Usha Dhingra, Larry Rand, Joanne Chappell, Gerald F Combs, Per Ashorn, James A Litch, Ulla Ashorn, Monjur Rahman, Kelli K. Ryckman, Daniel E Roth, Craig Lacher, Elizabeth Belling, Jane E. Hirst, Courtney Baruch-Gravett, Louis J. Muglia, Mohammed Hamad Juma, Waqasuddin Khan, Ge Zhang, Nabidul H. Chowdhury, Jeffrey S. A. Stringer, Said Mohamed Ali, Huan Xu, Susan K. Murphy, Tahmeed Ahmed, Salahuddin Ahmed, Laura Goodfellow, Kenneth Maleta, Arup Dutta, Juhi K. Gupta, Jesmin Pervin, Zarko Alfirevic, Rajiv Bahl, Ana Alfirevic, Le Quang Thanh, Fansheng Kong, Laura L. Jelliffe-Pawlowski, and Furqan Kabir
- Subjects
Pregnancy ,business.industry ,Meta-analysis ,Statistical significance ,Cohort ,medicine ,Global health ,Gestation ,Fixed effects model ,Logistic regression ,medicine.disease ,business ,Demography - Abstract
Background: Selenium (Se), an essential trace mineral, has been implicated in preterm birth (PTB). We aimed to determine the association of maternal Se concentrations during pregnancy with PTB risk and gestational duration in a large number of samples collected from diverse populations. Methods: Gestational duration data and maternal plasma or serum samples of 9946 singleton live births were obtained from 17 geographically diverse study cohorts. Maternal Se concentrations were determined by Inductively coupled plasma mass spectrometry (ICP-MS) analysis. The associations between maternal Se with PTB and gestational duration were analyzed using linear and logistic regressions. The results were then combined using fixed and random effect meta-analysis. Findings: In all study samples, the Se concentrations followed a normal distribution with a mean of 93.8 ng/ml (range: 26.1 to 228.7 ng/ml) but varied substantially across different sites. The fixed-effect meta-analysis across the 17 cohorts showed that Se was significantly associated with PTB (p = 0.04) and gestational duration (p = 2.9e-6) with effect size estimates of an OR= 1.04 (95% CI: 1.0 to 1.07) for PTB per 10 ng/ml decrease in Se concentration and 0.44 days (95% CI: 0.26 – 0.62) longer gestation per 10 ng/ml increase in Se concentration. However, there was a substantial heterogeneity among study cohorts. The largest effect sizes were observed in UK (Liverpool) cohort, while the most statistically significant associations were observed in samples from Malawi. After excluding these two cohorts, the fixed effect meta-analysis was no longer significant, and the random-effect meta-analysis of all data sets also did not achieve statistical significance. Interpretation: While our study observed statistically significant associations between maternal Se concentration and PTB at some sites, this did not generalize across the entire cohort. Whether population-specific factors explain the heterogeneity of our findings warrants further investigation. Targeted Se supplementation could play a role in reducing PTB in some settings, however further evidence is needed to understand the biologic pathways, clinical efficacy and safety, before changes to antenatal nutritional recommendations are considered. Funding Statement: Payment for access to data and article-processing charges for this publication was covered by The Bill & Melinda Gates Foundation (Grant no: OPP1175128, OPP1152451). The NEST study acknowledges the support from National Institute of Environmental Health Sciences, the US Environmental Protection Agency, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Duke Cancer Institute. Th CPPOP study acknowledge support from the UCSF California Preterm Birth Initiative. The iLiNS-DYAD-M trial acknowledge the support by a grant to the University of California, Davis from The Bill & Melinda Gates Foundation [OPP49817] and a grant to the University of California, Davis from the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, U.S. Agency for International Development (USAID) through the Food and Nutrition Technical Assistance III Project (FANTA). MDIG, AMANHI, GAPPS and INTERBIO cohorts acknowledge the support by The Bill & Melinda Gates Foundation. Declaration of Interests: The authors declare no conflicts of interest regarding the content of this paper. Ethics Approval Statement: Our study protocol was approved by the Institute Review Board (IRB) of the CCHMC and by the corresponding Ethics Committees of each participating institution.
- Published
- 2020
36. Placenta Praevia and Placenta Accreta: Diagnosis and Management
- Author
-
Sally Collins, Davor Jurkovic, Gynaecologists, Zarko Alfirevic, Robert M. Silver, Amar Bhide, S Dornan, Loïc Sentilhes, Gilles Kayem, Michael A. Belfort, Graham J. Burton, John Kingdom, and Erm Jauniaux
- Subjects
medicine.medical_specialty ,Placenta accreta ,Placenta Previa ,MEDLINE ,Placenta Accreta ,Ultrasonography, Prenatal ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Risk Factors ,Placenta ,medicine ,Humans ,030212 general & internal medicine ,030219 obstetrics & reproductive medicine ,Cesarean Section ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,Guideline ,medicine.disease ,medicine.anatomical_structure ,Premature birth ,Premature Birth ,Female ,Ultrasonography ,business ,Medical science - Published
- 2018
37. Prenatal reflex DNA screening for trisomies 21, 18, and 13
- Author
-
Wayne J. Huttly, Joe Aquilina, Devender Roberts, Zarko Alfirevic, Ray Cheng, Joan K. Morris, Jonathan P. Bestwick, Nicholas J. Wald, Robert Old, and Elisabeth Peregrine
- Subjects
medicine.medical_specialty ,Pregnancy ,Down syndrome ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,medicine.disease ,Confidence interval ,03 medical and health sciences ,0302 clinical medicine ,Nuchal translucency ,030220 oncology & carcinogenesis ,medicine ,False positive paradox ,Reflex ,Combined test ,business ,Routine care ,Genetics (clinical) - Abstract
The purpose of the study was to determine the screening performance of prenatal reflex DNA screening for trisomies 21 (T21), 18 (T18), and 13 (T13) as part of a routine service at five hospitals. Women who accepted screening had a first-trimester combined test (pregnancy-associated plasma protein A, free β-human chorionic gonadotropin, nuchal translucency interpreted with maternal age). Those with a risk of having an affected pregnancy ≥1 in 800 were reflexed to a DNA sequencing test using stored plasma from the original blood sample, thereby avoiding the need to recall them. Of 22,812 women screened (including 106 with affected pregnancies), 2,480 (10.9%) were reflexed to DNA testing; 101/106 were detected (69/73 T21, 24/25 T18, and 8/8 T13), a 95% detection rate (95% confidence interval 89–98%) with four false positives (0.02%, 95% confidence interval 0.00–0.05%). The odds of being affected given a positive result were 25:1. Of the 105 screen-positive pregnancies, 91 (87%) had an invasive diagnostic test. Reflex DNA screening avoided up to 530 invasive diagnostic tests compared with using the combined test. Reflex DNA screening was successfully implemented in routine care, achieving a high detection rate, low false-positive rate, and, consequently, greater safety with fewer invasive diagnostic tests than other methods of screening.
- Published
- 2018
38. Prenatal surgery for spina bifida
- Author
-
Axel Heep, Amanda Ali, Kelly-Ann Eastwood, Jan Deprest, Alyson Hunter, Fergal D. Malone, Fionnuala M. McAuliffe, Janusz Bohosiewicz, Katie Morris, Stephen Ong, Mano Shanmuganathan, Carolyn Bailie, Cathy McKillop, Deborah A Sival, Agnieszka Pastuszka, Darach Crimmins, Roy McConnell, Jacqueline Cartmill, and Zarko Alfirevic
- Subjects
medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Fetoscopic surgery ,medicine.medical_treatment ,education ,Prenatal surgery ,Postnatal surgery ,03 medical and health sciences ,0302 clinical medicine ,Obstetrics and gynaecology ,Pregnancy ,medicine ,Journal Article ,INVASIVE FETOSCOPIC SURGERY ,MANAGEMENT ,Humans ,Open prenatal surgery ,030212 general & internal medicine ,FETAL SURGERY ,Spinal Dysraphism ,Spina bifida ,reproductive and urinary physiology ,030219 obstetrics & reproductive medicine ,MYELOMENINGOCELE ,business.industry ,Fetal surgery ,TWIN TRANSFUSION SYNDROME ,Prenatal Care ,General Medicine ,medicine.disease ,Surgery ,nervous system diseases ,Dilemma ,Paediatric neurologist ,Systematic review ,Current practice ,Female ,Neurosurgery ,URINARY-TRACT OBSTRUCTION ,business ,Ireland ,INTERVENTION - Abstract
This is a transcript of a scientific conference on the subject of prenatal surgery for spina bifida. It represents the views of three patients, an obstetrician, a postnatal neurosurgeon, a neonatologist, a paediatric neurologist, two surgeons who practice open spina bifida foetal surgery, a fetoscopic surgeon and an obstetrician experienced in randomised trials and systematic reviews. Implications for current practice and recommendations for future research are also discussed in detail.
- Published
- 2018
39. Each baby counts in 2018 – lessons learned and future directions
- Author
-
AD Cameron, Ed Prosser-Snelling, HE Knight, Marian Knight, Louise Robertson, Zarko Alfirevic, and Emily Petch
- Subjects
business.industry ,Shared learning ,Obstetrics and Gynecology ,020207 software engineering ,02 engineering and technology ,Fetal monitoring ,03 medical and health sciences ,0302 clinical medicine ,Reproductive Medicine ,Nursing ,0202 electrical engineering, electronic engineering, information engineering ,Medicine ,Neonatal death ,business ,030217 neurology & neurosurgery - Abstract
The Royal College of Obstetricians and Gynaecologists (RCOG) launched the Each Baby Counts (EBC) project in 2015. The aim of the project is to reduce the number of stillbirths, early neonatal deaths and severe brain injuries in term babies born following labour by 50% by the year 2020. The first full report focussed on the quality of local reviews, fetal monitoring, individual human factors and neonatal care. For this article we have not focussed on the neonatal issues but have summarized the main points from each chapter. The aim of EBC will be achieved by focusing on three themes: (i) improving the quality of reviews of these babies, prompting local units to address their systematic failings that led to the outcome; (ii) development of toolkits and resources to support units to implement the recommendations in the report; (iii) improving care by establishing a platform for shared learning between units in order to adopt a more proactive approach to reducing babies who are harmed during labour.
- Published
- 2018
40. What women think about consent to research at the time of an obstetric emergency: a qualitative study of the views of a cohort of World Maternal Antifibrinolytic Trial participants
- Author
-
G Houghton, M Dower, Carol Kingdon, H Shakur-Still, and Zarko Alfirevic
- Subjects
Adult ,medicine.medical_specialty ,Biomedical Research ,Population ,Decision Making ,Context (language use) ,B720 ,Interviews as Topic ,Consent ,Cohort Studies ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Informed consent ,Pregnancy ,Medicine ,Childbirth ,Humans ,030212 general & internal medicine ,Plain language ,education ,education.field_of_study ,030219 obstetrics & reproductive medicine ,research ,Informed Consent ,business.industry ,Patient Selection ,Professional development ,Obstetrics and Gynecology ,A300 ,Waiver ,Data Accuracy ,Obstetric Labor Complications ,Intrapartum Care ,obstetric emergency ,Family medicine ,Female ,Patient Participation ,women's views ,Emergencies ,business ,Qualitative research - Abstract
Objective The World Maternal Antifibrinolytic (WOMAN) Trial was the first in the UK to use the option of waiver of informed consent at the time of an obstetric emergency. This qualitative study aimed to investigate participants’ views of the acceptability of the recruitment methods used. Design Qualitative study using in‐depth interviews with women who did and did not give consent at the time of their recruitment to the WOMAN Trial. Setting Highest UK recruitment site for the WOMAN Trial (129/569). Interviews were conducted in participants’ homes. Population About 40 of the 129 women who were recruited to the WOMAN Trial at one UK site were invited to take part, 15 women were interviewed. Methods Qualitative, interview study. Main outcome measures Facilitators and barriers to successful recruitment during obstetric emergencies. Guidance for future researchers. Results Findings revealed that what is important is not so much the consent process used or a signature on a form, but the way in which consent is obtained. Clinicians who successfully negotiate consent to research during childbirth emergencies engage in a ‘humane choreography’ of words and actions. This emphasises the importance of prompt decision‐making and treatment, while respecting the woman's personal situation and experience. Conclusions Our findings do not support a single pathway to consent in the context of an obstetric emergency. Women understand that consent to research in an emergency is complex. Clinicians’ skills in considering the clinical, ethical, and emotional aspects within the context of the clinical emergency can hamper or promote women's satisfaction. Tweetable abstract Study reports on women's views of consent to research in an obstetric emergency. Plain Language Summary Why and how was the study carried out? We undertook this study to find out what women thought about being included in a research study called the WOMAN Trial at the time they were being treated for heavy bleeding after giving birth. Some women had been asked if they wanted to be a part of the research at the time they were bleeding. Others were asked later, after they had recovered. We conducted interviews with 15 women who had been involved and asked what they thought about the way they had been asked, their preferences and ideas for improvements in future similar studies What were the main findings? Women understood how difficult it was for their doctors and midwives to ask them about the research study. They were pleased to have been included in the research and were mostly happy with the way they gave consent. Women's views were similar whether they were asked about the research at the time of the bleeding or after they had recovered. The most important thing was that doctors and midwives carefully thought about the situation the woman found herself in and how this might make her feel, so they could tailor their approach accordingly. What are the limitations of the work? This study only involved women from one hospital. The WOMAN Trial included women from many areas of the UK and other countries around the world. We do not know how their experiences or views may differ. What is the implication for professionals? Careful use of actions and words by birth attendants was the difference between a good or bad experience for the woman and her family. This is an important skill that could be developed as part of professional training., Tweetable abstract Study reports on women's views of consent to research in an obstetric emergency.
- Published
- 2018
41. How important is aspirin adherence when evaluating effectiveness of low-dose aspirin?
- Author
-
Zarko Alfirevic, Kate Navaratnam, Munir Pirmohamed, and Ana Alfirevic
- Subjects
medicine.medical_specialty ,Cardiology ,MEDLINE ,Alternative medicine ,030204 cardiovascular system & hematology ,Cochrane Library ,Medication Adherence ,03 medical and health sciences ,0302 clinical medicine ,Fibrinolytic Agents ,Pre-Eclampsia ,Pregnancy ,medicine ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Intensive care medicine ,Aspirin ,business.industry ,Obstetrics and Gynecology ,medicine.disease ,Surgery ,Obstetrics ,Reproductive Medicine ,Pill ,Female ,business ,Low dose aspirin ,medicine.drug - Abstract
Low-dose aspirin (LDA) is advocated for women at high-risk of pre-eclampsia, providing a modest, 10%, reduction in risk. Cardiology meta-analyses demonstrate 18% reduction in serious vascular events with LDA. Non-responsiveness to aspirin (sometimes termed aspirin resistance) and variable clinical effectiveness are often attributed to suboptimal adherence. The aim of this review was to identify the scope of adherence assessments in RCTs evaluating aspirin effectiveness in cardiology and obstetrics and discuss the quality of information provided by current methods. We searched MEDLINE, EMBASE and the Cochrane Library, limited to humans and English language, for RCTs evaluating aspirin in cardiology; 14/03/13-13/03/16 and pregnancy 1957-13/03/16. Search terms; ‘aspirin’, ‘acetylsalicylic acid’ appearing adjacent to ‘myocardial infarction’ or ‘pregnancy’, ‘pregnant’, ‘obstetric’ were used. 38% (25/68) of obstetric and 32% (20/62) of cardiology RCTs assessed aspirin adherence and 24% (6/25) and 29% (6/21) of obstetric and cardiology RCTs, respectively, defined acceptable adherence. Semi-quantitative methods (pill counts, medication weighing) prevailed in obstetric RCTs (93%), qualitative methods (interviews, questionnaires) were more frequent in obstetrics (67%). Two obstetric RCTs quantified serum thromboxane B 2 and salicylic acid, but no quantitative methods were used in cardiology Aspirin has proven efficacy, but suboptimal adherence is widespread and difficult to accurately quantify. Little is currently known about aspirin adherence in pregnancy. RCTs evaluating aspirin effectiveness show over-reliance on qualitative adherence assessments vulnerable to inherent inaccuracies. Reliable adherence data is important to assess and optimise the clinical effectiveness of LDA. We propose that adherence should be formally assessed in future trials and that development of quantitative assessments may prove valuable for trial protocols.
- Published
- 2017
42. Does serial 3rd trimester ultrasound improve detection of small for gestational age babies: Comparison of screening policies in 2 European maternity units
- Author
-
Zarko Alfirevic, Umber Agarwal, Borna Poljak, Edina Berberovic, and Vesna Sokol Karadjole
- Subjects
Pediatrics ,medicine.medical_specialty ,Croatia ,Cost-Benefit Analysis ,Pregnancy Trimester, Third ,Psychological intervention ,Sensitivity and Specificity ,3rd trimester ,Ultrasonography, Prenatal ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Ultrasound screening ,Humans ,Medicine ,030212 general & internal medicine ,Retrospective Studies ,Fetal Growth Retardation ,030219 obstetrics & reproductive medicine ,business.industry ,ultrasound, screening, small for gaestational age baby ,Ultrasound ,Infant, Newborn ,Obstetrics and Gynecology ,Retrospective cohort study ,Preterm Births ,medicine.disease ,United Kingdom ,Reproductive Medicine ,Infant, Small for Gestational Age ,Small for gestational age ,Female ,business - Abstract
The aim of this study was to compare the diagnostic accuracy of routine versus selective small for gestational age babies screening policy using data from two European Maternity Units. Methods for the antenatal detection of small for gestational age babies (SGA) differ between countries. This was a retrospective cohort study from Liverpool Women’s Hospital, UK, that uses selective third trimester sonography and from the University Hospital Centre Zagreb, Croatia, that uses routine third trimester sonography for SGA detection. Screen positive cases were defined as pregnancies with estimated fetal weight (EFW)
- Published
- 2017
43. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial
- Author
-
Haleema Shakur, Ian Roberts, Bukola Fawole, Rizwana Chaudhri, Mohamed El-Sheikh, Adesina Akintan, Zahida Qureshi, Hussein Kidanto, Bellington Vwalika, Abdulfetah Abdulkadir, Saturday Etuk, Shehla Noor, Etienne Asonganyi, Zarko Alfirevic, Danielle Beaumont, Carine Ronsmans, Sabaratnam Arulkumaran, Adrian Grant, Kaosar Afsana, Metin Gülmezoglu, Beverley Hunt, Oladapo Olayemi, Iain Chalmers, Pisake Lumbiganon, Gilda Piaggio, Tony Brady, Diana Elbourne, Eni Balogun, Tracey Pepple, Danielle Prowse, Nigel Quashi, Lin Barneston, Collette Barrow, Lisa Cook, Lauren Frimley, Daniel Gilbert, Catherine Gilliam, Rob Jackson, Taemi Kawahara, Hakim Miah, Sergey Kostrov, Maria Ramos, Phil Edwards, Tom Godec, Sumaya Huque, Olujide Okunade, Olusade Adetayo, Aasia Kayani, Kiran Javaid, Chrstine Biryabarema, Robert Tchounzou, Mohan Regmi, Kastriot Dallaku, Mateus Sahani, Sayeba Akhter, Nicolas Meda, Anthony Kwame Dah, Olufemi Odekunle, Oluwabusola Monehin, Austin Ojo, Grace Akinbinu, Ifeoma Offiah, Ubong Akpan, Uduak Udofia, Useneno Okon, Ezukwa Omoronyia, Okpe James, Nike Bello, Blessed Adeyemi, Chris Aimakhu, Olufemi Akinsanya, Bamidele Adeleye, Oluwaseun Adeyemi, Kayode Oluwatosin, Abiodun Aboyeji, Abiodun Adeniran, Adebayo Adewale, Noah Olaomo, Lawrence Omo-Aghoja, Emmanuel Okpako, Lucky Oyeye, Francis Alu, John Ogudu, Ezekiel Ladan, Ibrahim Habib, Babasola Okusanya, Olatunde Onafowokan, David Isah, Abalaka Aye, Felix Okogbo, Egbaname Aigere, Mark Ogbiti, Temitope Onile, Olaide Salau, Yinka Amode, Kamil Shoretire, Adebola Owodunni, Kehinde Ologunde, Akintunde Ayinde, Moses Alao, Olalekan Awonuga, Babatunde Awolaja, Omololu Adegbola, Fatimah Habeebu-Adeyemi, Adeyemi Okunowo, Hadiza Idris, Ola Okike, Nneka Madueke, Josiah Mutihir, Nankat Joseph, Babatunde Adebudo, Adeniyi Fasanu, Olugbenga Akintunde, Olufemi Abidoye, Owigho Opreh, Sophia Udonwa, Gladys Dibia, Simeon Bazuaye, Arafat Ifemeje, Aniefiok Umoiyoho, Emmanuel Inyang-Etoh, Sununu Yusuf, Kayode Olayinka, Babalola Adeyemi, Olusegun Ajenifuja, Umar Ibrahim, Yusuf Baffah Adamu, Oluwarotimi Akinola, Grace Adekola-Oni, Paul Kua, Roseline Iheagwam, Audu Idrisa, Ado Geidam, Andrea Jogo, Joseph Agulebe, Joseph Ikechebelu, Onyebuchi Udegbunam, Jacob Awoleke, Oluseyi Adelekan, Hajaratu Sulayman, Nkeiruka Ameh, Nurudeen Onaolapo, Affiss Adelodun, William Golit, Dachollom Audu, Adetunji Adeniji, Folasade Oyelade, Lamaran Dattijo, Palmer Henry, Olabisi Loto, Odidika Umeora, Abraham Onwe, Emily Nzeribe, Bartthy Okorochukwu, Augustine Adeniyi, Emmanuel Gbejegbe, Akpojaro Ikpen, Ikemefuna Nwosu, Abdulrasaq Sambo, Olubunmi Ladipo, Sola Abubakar, Ola Nene Okike, Enyinnaya Chikwendu Nduka, Eziamaka Pauline Ezenkwele, Daniel Onwusulu, Theresa Azonima Irinyenikan, Swati Singh, Amaitari Bariweni, Hadiza Galadanci, Peter Achara, Osagie Osayande, Mohammed Gana, Kiran Jabeen, Ayesha Mobeen, Sadaf Mufti, Maliha Zafar, Basharat Ahmad, Maimoona Munawar, Jeharat Gul, Naseema Usman, Fehmida Shaheen, Mariam Tariq, Nadia Sadiq, Rabia Batool, Habiba Sharaf Ali, Manahil Jaffer, Asma Baloch, Noonari Mukhtiar, Tasneem Ashraf, Raheela Asmat, Salma Khudaidad, Ghazala Taj, Roshan Qazi, Saira Dars, Faryal Sardar, Sanobar Ashfaq, Saeeda Majeed, Sadaqat Jabeen, Rukhsana Karim, Farzana Burki, Syeda Rabia Bukhari, Fouzia Gul, Musarrat Jabeen, Akhtar Sherin, Qurratul Ain, Shahid Rao, Uzma Shaheen, Samina Manzoor, Shabween Masood, Shabana Rizvi, Anita Ali, Abida Sajid, Aisha Iftikhar, Shazia Batool, Lubna Dar, Shahenzad Sohail, Shazia Rasul, Shamsa Humayun, Rashida Sultana, Sofia Manzoor, Syeda Mazhar, Afshan Batool, Asia Nazir, Nasira Tasnim, Hajira Masood, Razia Khero, Neelam Surhio, Samana Aleem, Naila Israr, Saba Javed, Lubna Bashir, Samina Iqbal, Faiza Aleem, Rubina Sohail, Saima Iqbal, Samina Dojki, Alia Bano, Naseem Saba, Maimoona Hafeez, Nishat Akram, Riffat Shaheen, Haleema Hashmi, Sharmeen Arshad, Rubina Hussain, Sadia Khan, Nighat Shaheen, Safia Khalil, Pushpa Sachdev, Gulfareen Arain, Amtullah Zarreen, Sara Saeed, Shamayela Hanif, Nabia Tariq, Mahwish Jamil, Shama Chaudhry, Hina Rajani, Tayyiba Wasim, Summera Aslam, Nilofar Mustafa, Huma Quddusi, Sajila Karim, Shazia Sultana, Misbah Harim, Mohd Chohan, Nabila Salman, Fareesa Waqar, Shamsunnisa Sadia, Lubna Kahloon, Shehla Manzoor, Samar Amin, Umbreen Akram, Ambreen Ikram, Samina Kausar, Tahira Batool, Brigadier Naila, Tahir Kyani, Christine Biryabarema, Ruth Bulime, Regina Akello, Bernadette Nakawooya Lwasa, Joselyn Ayikoru, Christine Namulwasira, Patrick Komagum, Isabirye Rebecca, Nayiga Annet, Nakirigya Nuulu, Elizabeth Nionzima, Rose Bwotya, Margret Nankya, Sarah Babirye, Joseph Ngonzi, Cesar Sanchez, Nkonwa Innocent, Kusasira Anitah, Ayiko Jackson, Elizabeth Ndagire, Christine Nanyongo, Dominic Drametu, Grace Meregurwa, Francis Banya, Rita Atim, Emmanuel Byaruhanga, Lema Felix, Hussein Iman, Vincent Oyiengo, Peninah Waigi, Rose Wangui, Faiza Nassir, Musimbi Soita, Rophina Msengeti, Zeinab Zubier, Hillary Mabeya, Antony Wanjala, Henry Mwangi, Brian Liyayi, Evelyn Muthoka, Alfred Osoti, Amos Otara, Veronicah Ongwae, Victor Wanjohi, Bonface Musila, Kubasu Wekesa, Alex Nyakundi Bosire, Alice Ntem, Angeline Njoache, Alice Ashu, André Simo, Dorothy Keka, Kenfack Bruno, Amadou Ndouoya, Martin Saadio, Mesack Tchana, Odel Gwan, Pauline Assomo, Venantius Mutsu, Nji Eric, Pascal Foumane, Philemon Nsem, Jeanne Fouedjio, Ymele Fouelifack, Pierre Marie Tebeu, Georges Nko'ayissi, Eta Ngole Mbong, Wisal Nabag, Riham Desougi, Hadia Mustafa, Huida Eltaib, Taha Umbeli, Khalid Elfadl, Murwan Ibrahim, Abdalla Mohammed, Awadia Ali, Somia Abdelrahiem, Mohammed Musa, Khidir Awadalla, Samirra Ahmed, Mahdi Bushra, Omer Babiker, Hala Abdullahi, Mohamed Ahmed, Elhassan Safa, Huida Almardi, Duria Rayis, Saeed Abdelrahman Abdelgabar, Gillian Houghton, Andrew Sharpe, Jim Thornton, Nick Grace, Carys Smith, Kim Hinshaw, Dawn Edmundson, Paul Ayuk, Alison Bates, George Bugg, Joanne Wilkins, Clare Tower, Alysha Allibone, Eugene Oteng-Ntim, Ahmad Kazumari, Anna Danford, Matilda Ngarina, Muzdalifat Abeid, Khadija Mayumba, Magreth Zacharia, George Mtove, Leonard Madame, Anthony Massinde, Berno Mwambe, Rwakyendela Onesmo, Sebastian Kitengile Ganyaka, Shyam Gupta, Rabindra Bhatt, Ajay Agrawal, Pramila Pradhan, Nikita Dhakal, Punita Yadav, Gyanendra Karki, Bhola Ram Shrestha, Mwansa Lubeya, Jane Mumba, Willies Silwimba, Isaiah Hansingo, Noojiri Bopili, Ziche Makukula, Alexander Kawimbe, Mwansa Ketty Lubeya, Willard Mtambo, Mathew Ng'ambi, Saimir Cenameri, Ilir Tasha, Aferdita Kruja, Besnik Brahimaj, Armida Tola, Leon Kaza, Desire Tshombe, Elizabeth Buligho, Roger Paluku-Hamuli, Charles Kacha, Kato Faida, Badibanga Musau, Herman Kalyana, Phanny Simisi, Serge Mulyumba, Nzanzu Kikuhe Jason, Jean Robert Lubamba, Willis Missumba, Ferdousi Islam, Nazneen Begum, Ferdousi Chowdhury, Rokeya Begum, Farjana Basher, Nazlima Nargis, Abu Kholdun, Shahela Jesmin, Shrodha Paul, Hailemariam Segni, Getachew Ayana, William Haleke, Hassen Hussien, Fikre Geremew, Moussa Bambara, Adolphe Somé, Amadou Ly, Roamba Pabakba, Horace Fletcher, Leslie Samuels, Henry Opare-Addo, Roderick Larsen-Reindorf, Kwadwo Nyarko-Jectey, Glen Mola, Malts Wai, Magdy El Rahman, Wafaa Basta, Hussein Khamis, Maria Fernanda Escobar, Liliana Vallecilla, and Gabriel Essetchi Faye
- Subjects
medicine.medical_specialty ,Hysterectomy ,business.industry ,medicine.medical_treatment ,Placebo-controlled study ,General Medicine ,030204 cardiovascular system & hematology ,Placebo ,medicine.disease ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Relative risk ,Anesthesia ,Clinical endpoint ,medicine ,Caesarean section ,Maternal death ,030212 general & internal medicine ,business ,Tranexamic acid ,medicine.drug - Abstract
Background\ud Post-partum haemorrhage is the leading cause of maternal death worldwide. Early administration of tranexamic acid reduces deaths due to bleeding in trauma patients. We aimed to assess the effects of early administration of tranexamic acid on death, hysterectomy, and other relevant outcomes in women with post-partum haemorrhage.\ud \ud Methods\ud In this randomised, double-blind, placebo-controlled trial, we recruited women aged 16 years and older with a clinical diagnosis of post-partum haemorrhage after a vaginal birth or caesarean section from 193 hospitals in 21 countries. We randomly assigned women to receive either 1 g intravenous tranexamic acid or matching placebo in addition to usual care. If bleeding continued after 30 min, or stopped and restarted within 24 h of the first dose, a second dose of 1 g of tranexamic acid or placebo could be given. Patients were assigned by selection of a numbered treatment pack from a box containing eight numbered packs that were identical apart from the pack number. Participants, care givers, and those assessing outcomes were masked to allocation. We originally planned to enrol 15 000 women with a composite primary endpoint of death from all-causes or hysterectomy within 42 days of giving birth. However, during the trial it became apparent that the decision to conduct a hysterectomy was often made at the same time as randomisation. Although tranexamic acid could influence the risk of death in these cases, it could not affect the risk of hysterectomy. We therefore increased the sample size from 15 000 to 20 000 women in order to estimate the effect of tranexamic acid on the risk of death from post-partum haemorrhage. All analyses were done on an intention-to-treat basis. This trial is registered with ISRCTN76912190 (Dec 8, 2008); ClinicalTrials.gov, number NCT00872469; and PACTR201007000192283.\ud \ud Findings\ud Between March, 2010, and April, 2016, 20 060 women were enrolled and randomly assigned to receive tranexamic acid (n=10 051) or placebo (n=10 009), of whom 10 036 and 9985, respectively, were included in the analysis. Death due to bleeding was significantly reduced in women given tranexamic acid (155 [1·5%] of 10 036 patients vs 191 [1·9%] of 9985 in the placebo group, risk ratio [RR] 0·81, 95% CI 0·65–1·00; p=0·045), especially in women given treatment within 3 h of giving birth (89 [1·2%] in the tranexamic acid group vs 127 [1·7%] in the placebo group, RR 0·69, 95% CI 0·52–0·91; p=0·008). All other causes of death did not differ significantly by group. Hysterectomy was not reduced with tranexamic acid (358 [3·6%] patients in the tranexamic acid group vs 351 [3·5%] in the placebo group, RR 1·02, 95% CI 0·88–1·07; p=0·84). The composite primary endpoint of death from all causes or hysterectomy was not reduced with tranexamic acid (534 [5·3%] deaths or hysterectomies in the tranexamic acid group vs 546 [5·5%] in the placebo group, RR 0·97, 95% CI 0·87-1·09; p=0·65). Adverse events (including thromboembolic events) did not differ significantly in the tranexamic acid versus placebo group.\ud \ud Interpretation\ud Tranexamic acid reduces death due to bleeding in women with post-partum haemorrhage with no adverse effects. When used as a treatment for postpartum haemorrhage, tranexamic acid should be given as soon as possible after bleeding onset.\ud \ud Funding\ud London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation.
- Published
- 2017
44. Diagnostic accuracy of individual antenatal tools for prediction of small-for-gestational age at birth
- Author
-
Andrew Sharp, Borna Poljak, Richard J. Jackson, Umber Agarwal, and Zarko Alfirevic
- Subjects
Pregnancy ,medicine.medical_specialty ,Pediatrics ,030219 obstetrics & reproductive medicine ,Radiological and Ultrasound Technology ,business.industry ,Obstetrics ,Birth weight ,Obstetrics and Gynecology ,Diagnostic accuracy ,General Medicine ,medicine.disease ,Likelihood ratios in diagnostic testing ,03 medical and health sciences ,0302 clinical medicine ,Reproductive Medicine ,Chart ,Medicine ,Small for gestational age ,Gestation ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,business ,Prospective cohort study - Abstract
Objective To determine the accuracy of fetal and newborn growth charts for the prediction of small‐for‐gestational age (SGA ) at birth (birth weight
- Published
- 2017
45. Cervical length screening for prevention of preterm birth in singleton pregnancy with threatened preterm labor: systematic review and meta‐analysis of randomized controlled trials using individual patient‐level data
- Author
-
Amen Ness, Zarko Alfirevic, Vincenzo Berghella, Montserrat Palacio, Kypros H. Nicolaides, Gabriele Saccone, Berghella, V., Palacio, M., Ness, A., Alfirevic, Z., Nicolaides, K. H., and Saccone, G.
- Subjects
preterm labor ,medicine.medical_specialty ,Singleton pregnancy ,Preterm labor ,Cervix Uteri ,law.invention ,transvaginal ultrasound ,03 medical and health sciences ,Obstetric Labor, Premature ,0302 clinical medicine ,Threatened Preterm Labor ,Randomized controlled trial ,Pregnancy ,law ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Cervical length ,Randomized Controlled Trials as Topic ,Ultrasonography ,Gynecology ,030219 obstetrics & reproductive medicine ,Radiological and Ultrasound Technology ,business.industry ,preterm birth ,Obstetrics and Gynecology ,General Medicine ,cervical length ,Transvaginal ultrasound ,Reproductive Medicine ,Cervical Length Measurement ,Patient level data ,Meta-analysis ,Premature Birth ,Female ,business ,Human - Abstract
Objective Cervical length screening by transvaginal sonography (TVS) has been shown to be a good predictive test for spontaneous preterm birth (PTB) in symptomatic singleton pregnancy with threatened preterm labor (PTL). The aim of this review and meta-analysis of individual participant data was to evaluate the effect of knowledge of the TVS cervical length (CL) in preventing PTB in singleton pregnancies presenting with threatened PTL. Methods We searched the Cochrane Pregnancy and Childbirth Group's Trials Register and the Cochrane Complementary Medicine Field's Trials Register (May 2016) and reference lists of retrieved studies. Selection criteria included randomized controlled trials of singleton gestations with threatened PTL randomized to management based mainly on CL screening (intervention group), or CL screening with no knowledge of results or no CL screening (control group). Participants included women with singleton gestations at 23 + 0 to 36 + 6 weeks with threatened PTL. We contacted corresponding authors of included trials to request access to the data and perform a meta-analysis of individual participant data. Data provided by the investigators were merged into a master database constructed specifically for the review. The primary outcome was PTB < 37 weeks. Summary measures were reported as relative risk (RR) or as mean difference (MD) with 95% CI. Results Three trials including a total of 287 singleton gestations with threatened PTL between 24 + 0 and 35 + 6 weeks were included in the meta-analysis, of which 145 were randomized to CL screening with knowledge of results and 142 to no knowledge of CL. Compared with the control group, women who were randomized to the known CL group had a significantly lower rate of PTB < 37 weeks (22.1% vs 34.5%; RR, 0.64 (95% CI, 0.44–0.94); three trials; 287 participants) and a later gestational age at delivery (MD, 0.64 (95% CI, 0.03–1.25) weeks; MD, 4.48 (95% CI, 1.18–8.98) days; three trials; 287 participants). All other outcomes for which there were available data were similar in the two groups. Conclusions There is a significant association between knowledge of TVS CL and lower incidence of PTB and later gestational age at delivery in symptomatic singleton gestations with threatened PTL. Given that in the meta-analysis we found a significant 36% reduction in the primary outcome, but other outcomes were mostly statistically similar, further study needs to be undertaken to understand better whether the predictive characteristics of CL screening by TVS can be translated into better clinical management and therefore better outcomes and under what circumstances. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Cribado mediante la longitud cervical para la prevencion del parto pretermino en embarazos con feto unico y riesgo de parto prematuro: revision sistematica y metaanalisis de ensayos controlados aleatorizados haciendo uso de los datos individuales de las pacientes RESUMEN Objetivo El cribado mediante la longitud cervical obtenida con ecografia transvaginal (ETV) ha demostrado ser una buena prueba para la prediccion del parto pretermino espontaneo (PPTE) en embarazos con feto unico sintomaticos debido a la amenaza de parto pretermino (PPT). El objetivo de esta revision y metaanalisis de los datos de participantes individuales fue evaluar el efecto de medir la longitud cervical (LC) mediante ETV con el fin de prevenir el parto prematuro en embarazos unicos con amenaza de PPT. Metodos Se realizaron busquedas en los ficheros de ensayos de Cochrane Pregnancy and Childbirth Group y Complementary Medicine Field (mayo de 2016), y en las listas de referencias de los estudios encontrados. Los criterios de seleccion incluyeron ensayos controlados aleatorizados de embarazos con feto unico y riesgo de PPT con aleatorizacion de la paciente basada principalmente en el cribado mediante la LC (grupo de intervencion), el cribado mediante la LC sin conocimiento de los resultados, o sin cribado de LC (grupo de control). Las participantes fueron mujeres embarazadas con feto unico desde las 23 + 0 hasta las 36 + 6 semanas y con riesgo de PPT. Se establecio contacto con los autores de los ensayos incluidos para solicitar el acceso a los datos y llevar a cabo un metaanalisis de los datos de las participantes individualmente. Los datos proporcionados por los investigadores se agregaron a una base de datos maestra creada especificamente para esta revision. El resultado primario fue el PPTE < 37 semanas. Las medidas resumen se reportaron como riesgo relativo (RR) o como diferencia de medias (DM) con IC del 95%. Resultados En el metaanalisis se incluyeron tres ensayos con un total de 287 embarazos con feto unico y riesgo de PPT entre 24 + 0 y 35 + 6 semanas, de los cuales 145 fueron asignados al azar a un cribado mediante la LC con conocimiento de los resultados y 142 a aquellos para los que se desconocia la LC. En comparacion con el grupo control, las mujeres que fueron asignadas aleatoriamente al grupo en el que se conocia la LC tuvieron una tasa de parto prematuro a < 37 semanas significativamente menor (22,1% vs. 34,5%; RR 0,64 (IC 95%, 0,44–0,94); 3 ensayos; 287 participantes ) y una edad gestacional al momento del parto mas tardia (DM 0,64 (IC 95%, 0.03–1.25) semanas; DM 4,48 (IC 95%, 1,18–8,98) dias; 3 ensayos; 287 participantes). El resto de los resultados para los cuales habia datos disponibles fueron similares en ambos grupos. Conclusiones Existe una asociacion significativa entre el conocimiento de la LC obtenida mediante ETV y una menor incidencia de PPTE y edad gestacional mas tardia en el momento del parto en embarazos con feto unico sintomaticos debido al riesgo de parto pretermino (PPT). Teniendo en cuenta que en el metaanalisis se encontro una reduccion significativa del 36% en el resultado primario, pero que los otros resultados fueron estadisticamente similares en su mayoria, seran necesarios mas estudios para entender mejor si las propiedades predictivas del cribado mediante la LC obtenida con ETV se pueden traducir en una mejor atencion clinica y por lo tanto mejores resultados dependiendo de las circunstancias. 出现先兆早产的单胎妊娠中筛查宫颈长度预防早产的发生:采用单个病例数据进行随机对照试验的系统综述和meta分析 目的 已有研究显示,在出现先兆早产(preterm labor,PTL)的有症状的单胎妊娠中,采用经阴道超声检查(transvaginal sonography,TVS)进行宫颈长度筛查是一种很好的预测自发性早产(spontaneous preterm birth,PTB)发生的方法。本篇对单个病例数据的综述和meta分析的目的是评估在出现先兆PTL的单胎妊娠中,知晓TVS宫颈长度(cervical length,CL)对预防PTB的作用。 方法 检索Cochrane妊娠和分娩组试验注册资料库和Cochrane辅助医学试验注册资料库(2016年5月)以及检索到的研究的参考文献列表。纳入标准为出现先兆PTL的单胎妊娠的随机对照试验,随机分为主要根据CL筛查结果进行处理(干预组)或者进行CL筛查但不知晓结果或未进行CL筛查(对照组)。研究对象为孕23 + 0周至孕36+6周出现先兆PTL的单胎妊娠孕妇。我们与纳入试验的通信作者取得联系,获准使用数据,并进行单个病例数据的meta分析。将研究人员提供的数据合并到特别建立的主数据库中以进行评价。主要结局为孕37周前发生PTB。综合检测结果以相对危险度(relative risk,RR)或平均差和95%CI(mean difference,MD)表示。 结果 meta分析纳入3项试验,共包括287例在孕24 + 0周至孕35+6周间出现先兆PTL的单胎妊娠,其中145例随机分至知晓结果的CL筛查组,142例分至不知晓CL组。与对照组相比,随机分至知晓CL组的孕妇孕37周前PTB发生率明显较低[22.1%和34.5%;RR,0.64(95% CI,0.44 ~ 0.94);3项试验;287名研究对象],分娩孕周延长[MD,0.64(95% CI,0.03 ~ 1.25)周;MD,4.48(95% CI,1.18 ~ 8.98)天;3项试验;287研究对象]。2组相比,现有数据的所有其他结局相似。 结论 出现先兆PTL的有症状的单胎妊娠中,知晓TVS CL与PTB发病率较低和分娩孕周延长呈显著相关。鉴于在meta分析中我们发现主要结局发生率显著降低36%,而其他结局大多统计学相似,因此需要进行进一步研究,以更深入了解采用TVS进行CL筛查的预测特点能否以及在何种情况下可以用于进行更好的临床管理,从而得到更好的结局。
- Published
- 2017
46. Vein of Galen aneurysmal malformation affecting cotwin in dichorionic diamniotic pregnancy
- Author
-
S. Burn, Andrew Sharp, Umber Agarwal, M. Sadiq, J. Hackett, L. Hall, Zarko Alfirevic, M. Putheran, and B. Hall
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pregnancy Trimester, Third ,Ultrasonography, Prenatal ,Diagnosis, Differential ,Fatal Outcome ,Text mining ,Pregnancy ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Vein ,Radiological and Ultrasound Technology ,business.industry ,Infant, Newborn ,Obstetrics and Gynecology ,General Medicine ,medicine.disease ,Surgery ,medicine.anatomical_structure ,Reproductive Medicine ,Vein of Galen Malformations ,Pregnancy, Twin ,Female ,business - Published
- 2020
47. Interventions to prevent spontaneous preterm birth in high-risk women with singleton pregnancy: a systematic review and network meta-analysis
- Author
-
Sarah J Nevitt, Sarah Donegan, Catrin Tudur Smith, Zarko Alfirevic, Nancy Medley, Laura Goodfellow, Deborah M Caldwell, and Lynn Hampson
- Subjects
Medicine General & Introductory Medical Sciences ,medicine.medical_specialty ,Cochrane collaboration ,Singleton pregnancy ,business.industry ,Obstetrics ,education ,Psychological intervention ,Individual risk ,Asymptomatic ,03 medical and health sciences ,0302 clinical medicine ,Intervention (counseling) ,Meta-analysis ,Medicine ,Pharmacology (medical) ,030212 general & internal medicine ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Cervical length - Abstract
© 2019 The Cochrane Collaboration. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To compare the efficacy of current, relevant interventions to prevent preterm birth in women with singleton pregnancy and high individual risk of spontaneous preterm birth. We will consider interventions for women with a history of spontaneous preterm birth or short cervical length and women with asymptomatic vaginal infections.
- Published
- 2019
48. Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial
- Author
-
Lucy C Chappell, Peter Brocklehurst, Marcus E Green, Rachael Hunter, Pollyanna Hardy, Edmund Juszczak, Louise Linsell, Virginia Chiocchia, Melanie Greenland, Anna Placzek, John Townend, Neil Marlow, Jane Sandall, Andrew Shennan, Umber Agarwal, Irshad Ahmed, Bini Ajay, Zarko Alfirevic, Rita Arya, Gabrielle Bambridge, Jacqueline Bamfo, Sambita Basak, Ursula Bowler, Helen Cameron, David Churchill, Janet Cresswell, Fiona Crosfill, Mark Denbow, Madhuchanda Dey, Caroline Everden, Jo Ficquet, Katarzyna Gajewska-Knapik, Ramesh Ganapathy, Angela Garrett, Joanna Girling, Adam Gornall, Kate Harding, Eleanor Hendy, Richard Howard, Mark James, Antoinette Johnson, Michelle Kemp, Asma Khalil, Rehan Khan, Rahila Khan, Ellen Knox, Lavinia Margarit, Philippa Marsden, Karen McIntyre, Jenny Myers, Justine Nugent, Sanjay Rao, Zoey Robinson, Stephen Robson, Pauline Rushby, Laura Scholz, Mohamed Shahin, Bhavna Sharma, Nigel Simpson, Natasha Singh, Jenie Sparkes, Sophia Stone, Seni Subair, Bee Tan, Vidya Thakur, Sujatha Thamban, Jim Thornton, Sue Tohill, Elly Tsoi, Derek Tuffnell, Mark Waterstone, Jason Waugh, Cornelia Wiesender, and Pensee Wu
- Subjects
medicine.medical_specialty ,Pregnancy ,Intention-to-treat analysis ,Eclampsia ,RJ ,Obstetrics ,business.industry ,RJ101 ,Gestational age ,General Medicine ,030204 cardiovascular system & hematology ,medicine.disease ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Premature birth ,Relative risk ,medicine ,Maternal death ,030212 general & internal medicine ,RG ,business - Abstract
Background: In women with late preterm pre-eclampsia, the optimal time to initiate delivery is unclear because limitation of maternal disease progression needs to be balanced against infant complications. The aim of this trial was to determine whether planned earlier initiation of delivery reduces maternal adverse outcomes without substantial worsening of neonatal or infant outcomes, compared with expectant management (usual care) in women with late preterm pre-eclampsia. Methods: In this parallel-group, non-masked, multicentre, randomised controlled trial done in 46 maternity units across England and Wales, we compared planned delivery versus expectant management (usual care) with individual randomisation in women with late preterm pre-eclampsia from 34 to less than 37 weeks' gestation and a singleton or dichorionic diamniotic twin pregnancy. The co-primary maternal outcome was a composite of maternal morbidity or recorded systolic blood pressure of at least 160 mm Hg with a superiority hypothesis. The co-primary perinatal outcome was a composite of perinatal deaths or neonatal unit admission up to infant hospital discharge with a non-inferiority hypothesis (non-inferiority margin of 10% difference in incidence). Analyses were by intention to treat, together with a per-protocol analysis for the perinatal outcome. The trial was prospectively registered with the ISRCTN registry, ISRCTN01879376. The trial is closed to recruitment but follow-up is ongoing. Findings: Between Sept 29, 2014, and Dec 10, 2018, 901 women were recruited. 450 women (448 women and 471 infants analysed) were allocated to planned delivery and 451 women (451 women and 475 infants analysed) to expectant management. The incidence of the co-primary maternal outcome was significantly lower in the planned delivery group (289 [65%] women) compared with the expectant management group (338 [75%] women; adjusted relative risk 0·86, 95% CI 0·79–0·94; p=0·0005). The incidence of the co-primary perinatal outcome by intention to treat was significantly higher in the planned delivery group (196 [42%] infants) compared with the expectant management group (159 [34%] infants; 1·26, 1·08–1·47; p=0·0034). The results from the per-protocol analysis were similar. There were nine serious adverse events in the planned delivery group and 12 in the expectant management group. Interpretation: There is strong evidence to suggest that planned delivery reduces maternal morbidity and severe hypertension compared with expectant management, with more neonatal unit admissions related to prematurity but no indicators of greater neonatal morbidity. This trade-off should be discussed with women with late preterm pre-eclampsia to allow shared decision making on timing of delivery. Funding: National Institute for Health Research Health Technology Assessment Programme.
- Published
- 2019
49. Reducing the impact of preterm birth::Preterm birth commissioning in the United Kingdom
- Author
-
Lisa Story, Zarko Alfirevic Z, Phillip R. Bennett, Matthew Jolly, Anna L. David, Andrew Shennan, and Nigel Simpson
- Subjects
medicine.medical_specialty ,business.industry ,Project commissioning ,Best practice ,Safer maternity care ,Obstetrics and Gynecology ,Preterm birth ,Review ,lcsh:Gynecology and obstetrics ,Care provision ,Maternity care ,Reproductive Medicine ,SAFER ,Expert opinion ,Family medicine ,Medicine ,business ,lcsh:RG1-991 ,UK commissioning guidance - Abstract
Reducing preterm birth is a priority for Maternity and Children’s services. In the recent UK Department of Health publication ‘Safer Maternity Care’ the Secretary of State for Health aimed to achieve the national maternity safety ambition by pledging to reduce the rate of preterm birth from 8% to 6%. It was proposed that specialist preterm birth services should be established in the UK in order to achieve this aim. In response the Preterm Clinical Network has written Commissioning Guidance aimed to establish best practice pathways and agreed models of care to reduce variation nationally. They have been developed by clinical experts in the field, from within the UK, to provide recommendations for commissioning groups and to recommend pathways to organisations with the aim of reducing the incidence of preterm birth. Three key areas of care provision are focused on: prediction, prevention and preparation of women at high risk of PTB. This Expert Opinion, will summarise the Commissioning Guidance. Keywords: Preterm birth, UK commissioning guidance, Safer maternity care
- Published
- 2019
50. Challenges in Designing Clinical Trials to Test New Drugs in the Pregnant Woman and Fetus
- Author
-
Zarko Alfirevic, Louise C. Kenny, and Mark A. Turner
- Subjects
Public-Private Sector Partnerships ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Nursing ,Drug Development ,law ,Pregnancy ,Stakeholder Participation ,030225 pediatrics ,medicine ,Humans ,030212 general & internal medicine ,Clinical Trials as Topic ,Clinical pharmacology ,business.industry ,Obstetrics and Gynecology ,medicine.disease ,Test (assessment) ,Clinical trial ,Data sharing ,Pregnancy Complications ,Public–private partnership ,Fetal Diseases ,Drug development ,Pediatrics, Perinatology and Child Health ,Female ,Drugs in pregnancy ,business - Abstract
© 2019 Elsevier Inc. The need for new drugs in pregnancy is widely recognized. This review identifies several unique challenges and describes some solutions. Specific studies and drug development programs need careful planning that accounts for the needs of regulatory agencies. The perinatal (obstetric/pediatric) community needs to establish collaborations to develop methodologies, to facilitate data sharing, and to lobby for research and access to medicines. There is a need to gather and present information that promotes proportionate judgments of the balance between potential benefits and risks. This will require researchers to look beyond their traditional ways of working.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.